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ABSTRACT 
 
             Heparan sulfate proteoglycan (HSPG) or heparan sulfate (HS) 
degradation may contribute to endothelial cell (EC) dysfunction in diabetes. 
HSPGs, syndecan and perlecan, contain a protein core with mainly HS 
glycosaminoglycans (GAGs) attached. HSPGs modulate growth factors and 
function in membrane filtering.  Heparanase induction is likely responsible for 
diabetic HS degradation. Heparin protects endothelium and insulin regulates 
glucose metabolism. Our objectives were to observe HSPG changes by 
studying EC GAG content and gene expression of syndecan, perlecan and 
heparanase under hyperglycemic conditions with insulin and/or heparin 
treatment. 
          GAGs, including HS, were determined by the carbazole assay and 
visualized by agarose gel electrophoresis in porcine aortic EC cultures 
treated with high glucose (30 mM) and/or insulin (0.01 U/ml) for 24, 48 and 
72 hours and/or heparin (0.5 µg/ml) for 72 hours. High glucose decreased 
cell GAGs and increased medium GAGs. GAGs increased with time in 
control cultures and in high glucose plus insulin treated medium. GAGs were 
decreased with insulin but increased with insulin or heparin plus high 
glucose.  
 iv 
            Confluent cultured human aortic ECs were incubated with control 
medium, high glucose and/or insulin and/or heparin for 24 hours. Real time 
PCR determination showed that: high glucose increased heparanase, 
decreased syndecan and had no effect on perlecan mRNA; insulin or heparin 
with/without high glucose decreased and insulin and heparin with high 
glucose increased heparanase mRNA; heparin and insulin with high glucose 
increased but insulin decreased syndecan mRNA. Actinomycin D (10 µg/ml) 
inhibited heparanase and syndecan mRNA with high glucose plus insulin 
plus heparin and inhibited heparanase mRNA with high glucose compared to 
time 0 but not β-actin after addition for 0, 2, 4, 8 and 24 hours. Bioinformatic 
studies revealed that transcription factor Sp1 activates heparanase promoter 
by high glucose and may play a role in regulation of perlecan and syndecan 
promoters. 
            Insulin or heparin inhibited the reduction in EC GAGs and syndecan 
mRNA and induction in heparanase by high glucose, indicating their 
protective effect. Decreased GAGs by insulin may relate to the pathology of 
hyperinsulinemia. Transcriptional regulation by heparin and/or insulin may 
cause variation in gene expression of heparanase, syndecan and perlecan.  
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1. LITERATURE REVIEW 
 
1.1. Diabetes 
    1.1.1. Definition of Diabetes 
            Diabetes is defined as a disorder of carbohydrate metabolism. The 
most common form of diabetes is diabetes mellitus (DM) in which there is an 
inability to oxidize carbohydrate due to disturbances in insulin function. 
Insulin is the principal hormone released by pancreatic β-cells that regulates 
uptake of glucose into cells (primarily muscle and fat cells) from the blood. 
Insulin makes it possible for most body tissues to remove glucose from the 
blood for use as fuel, for conversion to other needed molecules, or for 
storage, e.g. insulin is the principal control signal for conversion of glucose  
to glycogen for storage in liver and muscle cells. If the amount of insulin 
produced is insufficient, or cells respond poorly to the effects of insulin 
(insulin insensitivity or resistance), or if the insulin itself is defective, glucose 
is not handled properly by body cells nor stored appropriately in the liver and 
muscle. The net effect is persistent high levels of blood glucose, poor protein 
synthesis, and other metabolic derangements. Therefore, DM is considered 
to be a group of diseases characterized by hyperglycemia resulting from 
defects in insulin production and action, or both. DM is typically classified into 
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two main subtypes: type 1 and type 2. Hyperglycemia defines both types of 
diabetes and has adverse effects on endothelial function and vascular 
reactivity (Mather et al., 2001b). Type 1 diabetes develops when the 
pancreatic β-cells are destroyed by the body’s autoimmune system and can 
not produce the insulin that regulates blood glucose. Type 2 diabetes usually 
begins as insulin resistance, a disorder in which the cells do not use insulin 
properly. As the need for insulin rises, the pancreas gradually loses its ability 
to produce or secrete insulin. Type 1 diabetes usually strikes children and 
young adults and may account for five to ten percent of all diagnoses of 
diabetes. Type 2 diabetes is associated with old age, obesity, family history 
of diabetes, prior history of gestational diabetes, impaired glucose tolerance, 
physical inactivity, and race/ethnicity and may account for 90 to 95 percent of 
all diagnosed cases of diabetes. Type 2 diabetes is increasingly being 
diagnosed in children and adolescents. The rate of new cases of type 2 was 
greater than the rate for type 1 diabetes at ages 10 to 19 years and a total of 
1.6 million new cases of diabetes were diagnosed in people in United States 
aged 20 years or older in 2007 (National Diabetes Statistics 2007). 
            In 2000, according to the World Health Organization (WHO), at least 
171 million people or 2.8% of the population worldwide suffer from diabetes 
(Wild et al., 2004). Its incidence is increasing rapidly, and it is estimated that 
by the year 2030, this number will almost double (Wild et al., 2004). DM 
occurs throughout the world, but is more common (especially type 2) in the 
more developed countries. The greatest increase in prevalence is, however, 
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expected to occur in Asia and Africa, where by 2030 most patients will likely 
be found probably due to urbanization and changes in lifestyle (Wild et al., 
2004). For at least 20 years, diabetes rates in North America have been 
increasing substantially. According to “Diabetes in Canada: Highlights from 
the National Diabetes Surveillance System”, the number of people with 
diagnosed diabetes continues to grow, with almost 200,000 new cases of 
diabetes diagnosed in 2005-2006. Approximately 1.9 million Canadian men 
and women had been diagnosed with diabetes. This represents about 1 in 17 
Canadians - 5.5 % of all women and 6.2 % of all men.  In 2008 there were 
approximately 24 million people with diabetes in the United States alone. 
About 5.7 million people remain undiagnosed. Another 57 million people are 
estimated to have pre-diabetes (hhttp://www.cdc.gov/Features/diabetes 
factsheet/). The National Diabetes Information Clearinghouse estimated that 
diabetes costs were $174 billion in the United States in 2007 (National 
Diabetes Statistics 2007).  
    1.1.2. Diabetic Cardiovascular Complications  
            Cardiovascular diseases are the major DM complications. Among 
them are vascular complications, such as angiopathy characterized by 
microvascular pathology in the retina and renal glomerulus and changes 
typical of arterial disease in the macrovasculature. These result in 
nephropathy, retinopathy and neuropathy in microvessels and 
atherosclerosis in macrovessels. Both microvascular and macrovascular 
diseases contribute greatly to the morbidity and mortality in diabetes (Kassab 
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et al., 2001). Diabetes is associated with accelerated atherosclerotic 
macrovascular disease affecting arteries that supply the heart, brain and 
lower extremities. As a result, patients with diabetes have a much higher risk 
of myocardial infarction, stroke, and limb amputation. It is well established 
that chronic hyperglycemia results in microvascular complications in diabetes 
which is the leading cause of renal failure and blindness. Up to 80% of 
deaths in people with type 2 diabetes are attributed to cardiovascular disease 
and stroke (Hanefeld et al., 1996).  
            Diabetic microvascular disease affects the small vessels such as 
those present in the retina, near nerves and in the microvasculature of the 
kidneys. This systemic disease in diabetes clinically leads to retinopathy and 
glomerular dysfunction, and possibly contributes to neuropathy. A number of 
studies have suggested that hyperglycemia appears to be the central 
initiating factor for all types of diabetic microvascular diseases (Kamata et al., 
1992; Ruderman et al., 1992). Some evidence derived from animal studies of 
experimental diabetes also showed lesions in the eye (Engerman and Kern, 
1984) and kidney (Engerman and Kern, 1989; Rasch, 1981) similar to those 
in humans. Patients under better glycemic control developed fewer eye 
and/or renal complications in a clinical study (Pirart, 1977). Non-proliferation 
diabetic retinopathy is associated with pericyte loss, formation of 
microaneurysms, increased vascular permeability, and capillary closure that 
can lead to areas of non-perfusion and ischemia. The retina responds to this 
hypoxia by increased production of vascular endothelial cell growth factor 
  
 5 
(VEGF), which promotes neovascularisation (Aiello et al., 1994). In diabetic 
nephropathy, an increase in both intraglomerular pressure and extracellular 
matrix (ECM) proteins results in basement membrane (BM) thickening, 
mesangial expansion, glomerular hypertrophy and narrowing of the lumen of 
the capillaries (Osterby et al., 1990). These changes reduce glomerular 
filtration area and function and impede blood flow. These alterations can 
progress to glomerulosclerosis (Mogensen et al., 1988), resulting in an 
increased albumin filtration rate and microalbuminuria (Deckert et al., 1989). 
Diabetic neuropathy refers to a group of diseases that affect the peripheral 
nerves which extend outside the brain and spinal cord and include three 
types: motor, sensory and autonomic nerves. The autonomic nerves, not 
consciously controlled, supply the heart, blood vessels, bladder and intestinal 
tract. Diabetic neuropathy is classified as either peripheral (including sensory 
and motor) or autonomic, with peripheral neuropathy being the most common 
manifestation. Diabetic neuropathy results from both chronic and acute 
elevations in blood glucose. Decreased nerve function by acute 
hyperglycemia and reduced nerve fibers and nerve fiber reproduction by 
chronic hyperglycemia, are believed to occur because of the formation of 
sorbitol and advanced glycosylation end-products (AGEs) (Clark, Jr. and Lee, 
1995) which cause microangiopathy resulting in altered neuronal capillary 
flow (Koda-kimble and Carlisle, 1995). 
            Macrovascular complications in diabetes, including coronary artery 
disease, peripheral vascular disease and cerebrovascular disease, are the 
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result of an acceleration of atherosclerosis and increased thrombosis. 
Although the relationship between hyperglycemia and macrovascular 
disease in patients with diabetes is complicated by many other factors that 
influence atherogenesis, an association between asymptomatic 
hyperglycemia and coronary heart disease has been found in both middle-
aged and elderly people (Jarrett et al., 1982; Mykkanen et al., 1990). Many 
factors, some of which may exist in the prediabetic state, particular in type 2 
diabetes, are involved in the etiology of macrovascular disease. 
Hyperlipidaemia, hypertension, hyperinsulinaemia and decreased insulin 
sensitivity related to the insulin-resistance syndrome have been proposed to 
induce atherogenesis even before the clinical diagnosis of type 2 diabetes 
(Haffner et al., 1990). In addition, diabetes is associated with coagulopathy 
and endothelial dysfunction with impaired nitric oxide (NO) production, 
compounding the effects of hyperglycemia in promoting atherogenesis (Jokel 
and Colwell., 1997). A number of factors, such as hyperinsulinaemia, insulin 
precursors, and tumor necrosis factor-α (TNF-α) are thought to increase 
plasma plasminogen activator inhibitor-1 (PAI-1) concentrations. Local 
changes in vascular PAI-1 expression, which is increased in the neointima of 
atherosclerotic lesions, may also have an impact on the fibrinolytic balance in 
injured vessels. High PAI-1 levels inhibit fibrinolysis and facilitate the 
persistence of fibrin, which may damage the endothelium (Lupu et al., 1993). 
Endothelial dysfunction may reduce the antithrombotic properties of the 
endothelium by decreasing the synthesis of prostaglandin I2 (PGI2) and 
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diminishing the endothelial protective effects against platelet adhesion (Wu 
and Thiagarajan, 1996). The common features in diabetic vascular disease, 
due to development of chronic hyperglycemia, are exaggerated proliferation 
of endothelium and BM thickening (Fischer et al., 1979; Kefalides, 1981; 
Osterby et al., 1990) which result in narrowing of the blood vessel lumen 
causing thrombosis, ischemia, and ultimately infarction (Colwell and Lopes-
Virella, 1988b).   
            Diabetic cardiomyopathy is characterized by cardiac contractile 
dysfunction and congestive heart failure due to myocellular hypertrophy and 
myocardial fibrosis (Hayat et al., 2004). This induces abnormal left ventricular 
filling with poor compliance or prolongation of left ventricular relaxation. The 
exact cause of this ventricular dysfunction is not known, but several 
mechanisms have been proposed, including metabolic abnormalities of 
glucose transport, increased ECM in the interstitium of the ventricular wall 
due to increased type IV collagen and a combination of nonenzymatic 
glycation and enzymatic O-linked glycosylation (Nishio et al., 1995), and 
abnormalities in fatty-acid metabolism and alteration of calcium uptake by the 
sarcoplasmic reticulum leading to cellular calcium overload. These changes 
can result in stiffer ventricular walls and impaired myocyte contractility 
(Mizushige et al., 2000; Tahiliani and McNeill, 1986). Macrovascular 
complications, leading to coronary heart disease may make a large 
contribution to heart failure in diabetic cardiomyopathy (Malmberg et al., 
2000). 
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    1.1.3. Molecular Mechanisms of Vascular Damage by     
              Hyperglycemia  
          Hyperglycemia is considered to be one of the most important 
predisposing factors in the development of diabetic complications (Kamata et 
al., 1992; Ruderman et al., 1992). In clinical studies, patients under better 
glycemic control develop fewer eye and/or renal complications (Pirart, 1977). 
Hyperglycemia causes cell damage which ultimately leads to irreversible 
structural abnormalities characterized by loss of cells and progressive 
microvascular occlusion in the eye and kidney, and by intimal proliferation 
and occlusion in large vessels (Bresnick et al., 1977; Osterby et al., 1990; 
Steffes et al., 1989).  Hyperglycemia-induced microvascular hypertension 
also contributes directly to an increase in vascular permeability, and the 
resultant extravasations of plasma proteins and growth factors, both in small 
and large vessels, may promote irreversible hypertension and vessel 
occlusion. Additional evidence is derived from studies showing that 
hyperglycemia associated with diabetes produce many of the metabolic, 
biochemical, and functional abnormalities seen in the vasculature. At least 
four different mechanisms have been postulated to contribute to these 
abnormalities.  
            The first mechanism which may contribute to diabetic complications is 
an increase in the formation of sorbitol (Bank et al., 1989; Pugliese et al., 
1990; Tilton et al., 1989). In the hyperglycemic state, excess glucose 
  
 9 
entering the polyol pathway can lead to the accumulation of sorbitol by 
aldose reductase coupled with oxidation of reduced nicotinamide-adenine 
dinucleotide phosphate (NADPH) to its oxidized form NADP+. Sorbitol can be 
subsequently converted to fructose by sorbitol dehydrogenase coupled with 
the reduction of oxidized nicotinamide-adenine dinucleotide (NAD+) to the 
reduced form NADH as shown in Figure 1.1. Aldose reductase is ubiquitous 
and therefore polyols accumulate in nearly all tissues of diabetic patients. 
Increased flux through this pathway due to hyperglycemia, increases 
intracellular sorbitol and fructose, increases osmotic pressure, decreases 
myoinositol concentration, and in combination with glycolysis, alters the 
intracellular redox balance. NADPH is required for NO regeneration and 
replenishes the antioxidant glutathione. Thus, the increased cytosolic 
NADH/NAD+ ratio decreases NADPH, resulting in the formation of 
intracellular reactive oxygen species (ROS), leading to oxidative stress 
(Brownlee, 2001). Certain abnormalities in the microvasculature of diabetic 
rats are prevented by administration of an inhibitor of aldose reductase 
(Beyer-Mears et al., 1986; Cohen, 1986; Craven and DeRubertis, 1989b; 
Robison, Jr. et al., 1989).   
            The second mechanism is decreased myoinositol-dependent Na/K- 
ATPase as shown in Figure 1.2. Myoinositol is a normal constituent of the 
diet and is also synthesized by many cells (Greene et al., 1987). It plays an 
important role in signal transduction and the synthesis of phosphoinositides       
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 (© Setter et al. 2003. Figure prepared by Dr. William Light on behalf of Medi Tech Media Ltd) 
Figure 1. 1.  Polyol Pathway 
Activation of the polyol pathway results in a decrease of reduced NADP
+
 and 
oxidized NAD+; these are necessary cofactors in redox reactions throughout the 
body. The reduction in these cofactors leads to decreased levels of reduced 
glutathione, NO and myoinositol. 
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(PI). Adenosine-mediated hydrolysis of PI leads to the release of a mediator 
that activates Na/K-ATPase and thereby regulates many cell functions. 
Depletion of the intracellular pool of PI caused by a sorbitol pathway-linked 
transport defect and a decrease in its response to adenosine both occur in 
diabetes, which can be prevented by aldose reductase inhibitors (Beyer-
Mears et al., 1986; Robison, Jr. et al., 1989; Winegrad, 1987).  
            The third mechanism is increased synthesis of diacylglycerol (DAG) 
with the consequent activation of several isoforms of protein kinase C (PKC) 
(Craven and DeRubertis, 1989a; Lee et al., 1989b; Pugliese et al., 1990). 
Several studies have shown that hyperglycemia increases DAG 
concentration in several types of vascular cells and tissues and causes an 
activation of PKC, probably by its translocation from cytosol to the membrane 
(Lee et al., 1989a,b). PKC is probably activated by DAG synthesized by 
means of a stepwise acylation of glycerol 3-phosphate generated as a by-
product of glycolysis. Increased DAG levels and activation of PKC have been 
linked to cell growth, permeability, contractility and synthesis of ECM proteins 
resulting in the abnormal vascular function associated with diabetes 
(Ruderman et al., 1992). 
             The fourth mechanism is covalent modification of protein by 
nonenzymatic glycosylation. Nonenzymatic glycosylation has been shown to 
result in qualitative and quantitative changes in extracellular components that 
can affect cell adhesion, growth, and matrix production
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                                                                                             (Clark and Lee, 1995) 
Figure 1.2. The Aldose Reductase Pathway of Glucose Metabolism 
The aldose reductase pathway is activated by intracellular hyperglycemia, resulting 
in increased sorbitol formation. This, in turn (through an unknown mechanism, 
indicated by the question mark), results in decreased myo-inositol formation and 
ultimately in decreased cellular activity of Na
+
K
+
-ATPase. Hyperglycemia also 
directly inhibits ATPase activity. The vertical arrows indicate increases (↑) and 
decreases (↓) in the substances in question. 
  
 13 
(Charonis et al., 1990; Sensi et al., 1989; Tsilibary et al., 1988). Many of 
these effects are mediated by AGEs, which form from Amadori products (1-
amino-1-deoxyketose) through a complex series of dehydration, 
rearrangements and redox reactions (Monnier and Cerami, 1983) as 
described in Figure 1.3. Matrix accumulation of AGEs may further accelerate 
diabetic vascular occlusion by blunting the effect of the vasodilatory factor 
NO, which is quenched by AGEs in a dose-dependent fashion (Bucala et al., 
1991). AGEs may exert their biological effects through the receptor for AGE 
(RAGE) coupled signaling pathway (Schmidt et al., 2000). Interaction of 
AGEs with endothelial RAGE may activate cellular events such as 
upregulation of transcription factor NF-kappaB, and activation of NAD(P)H-
oxidase and p38 MAP/ERK1/2 MAP kinase cascades (Bierhaus et al., 2005; 
Wautier et al., 2001). Transcriptional increase in RAGEs activate a number of 
genes relevant to atherogenesis including vascular cell adhesion molecule-1 
(VCAM-1), intracellular adhesion molecule-1 (ICAM-1), tissue factor, ET-1, 
and additional proinflammatory cytokines (Goldin et al., 2006). AGE/RAGE-
mediated gene expression induced intracellular ROS formation (Basta et al., 
2002). The production of ROS, AGE, RAGE, cytokines, and other gene 
products are involved in the development of diabetic complications and 
atherogenesis. 
            Alterations in four such interrelated hyperglycemia-driven pathways 
have been linked to the early microvascular changes associated with 
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                                                                                              (Clark and Lee, 1995) 
Figure 1.3. Formation of Advanced Glycosylation End Products from Glucose 
The formation of advanced glycosylation end-products (AGEs) from glucose occurs 
through the nonenzymatic formation of early glycosylation products (N-
glucosylamine) that then undergo acid-base catalysis to form Amadori products (1-
amino-1-deoxyketose). AGEs result from the degradation of the Amadori products 
into reactive carbonyl compounds that react with free amino groups (R-NH2). The 
formation of AGEs in vivo is retarded by reductase.  
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diabetes in animal and human tissues (Walker and Viberti, 1991; Williamson 
et al., 1988). Hyperglycemia can also contribute directly to microvascular              
occlusion by stimulating ECM synthesis (Brownlee and Spiro, 1979; Moran et 
al., 1991). Various abnormalities, such as increased AGEs, PKC and 
cytokines such as transforming growth factor-β (TGF-β), and increased 
oxidative stress in diabetes contribute to synthesis of ECM proteins, i.e. type 
IV collagen, laminin and fibronectin. In addition, loss of cells may indirectly 
contribute to further microvascular occlusion by stimulating excessive 
production of ECM (McNeil et al., 1989; Okuda et al., 1990; Saito et al., 
1988).   
    1.1.4. Insulin  
       1.1.4.1. Insulin Functions and Structure 
            Insulin, a circulatory hormone produced in response to elevated 
glucose concentration in the blood, regulates the metabolism of glucose. 
Glucose is liberated from dietary carbohydrate such as starch or sucrose by 
hydrolysis within the small intestine, and is then absorbed into the blood. 
Elevated concentrations of glucose in blood stimulate synthesis and 
secretion of insulin from pancreatic β-cells. Insulin acts on cells throughout 
the body to stimulate uptake, utilization and storage of glucose. Besides the 
role in regulating glucose metabolism, insulin stimulates lipogenesis, 
diminishes lipolysis, increases amino acid transport into cells, and modulates 
transcription, altering cell content of numerous mRNAs. Therefore, insulin is 
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able to stimulate cell growth, DNA synthesis, and cell replication, effects that 
it holds in common with insulin-like growth factors (Bornfeldt et al., 1992; 
Sowers, 1997).          
            Insulin is a rather small peptide consisting of two straight chains with 
a molecular weight of about 6 KDa. The A chain, containing 21 amino acids, 
and the B chain, containing 30 amino acids, are held together by two 
disulfide bonds. In addition, the A chain contains an intrachain disulfide ring 
(Figure 1.4). Although the amino acid sequence of insulin varies among 
species, the positions of the three disulfide bonds, the N-terminal and C-
terminal amino acid of the A chain, and the hydrophobic character of the 
amino acid at the C-terminal of B chain are highly conserved. These 
similarities in the amino acid sequence of insulin lead to a three dimensional 
conformation of insulin that is very similar among species and critical to 
biological activity.  Indeed, pig insulin has been widely used to treat human 
patients. Insulin molecules have a tendency to form dimers, three of which in 
the presence of zinc form a crystalline hexameric unit with a three-fold axis 
passing through two zinc atoms. Crystalline zinc insulin is the basic 
pharmaceutical preparation of greatest importance in therapy (Dodson and 
Steiner, 1998).   
       1.1.4.2. Biosynthesis of Insulin 
            Insulin is synthesized in significant quantities only in β-cells of the 
islets of Langerhans in the pancreas. The insulin gene on human 
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chromosome 11 is the ancestral member of a superfamily coding for a variety 
of related growth factors. The gene is composed of three exons and two 
introns. The insulin mRNA is translated as a single chain precursor called 
preproinsulin, molecular weight 11.5 KDa, containing four sequential 
peptides. After removal of its signal peptide during insertion into the 
endoplasmic reticulum, proinsulin is generated with three other peptides: an 
amino-terminal B chain, a carboxy-terminal A chain and a connecting peptide 
in the middle known as the C peptide. Within the endoplasmic reticulum, 
proinsulin is exposed to several specific endopeptidases which excise the C 
peptide, thereby generating the mature form of insulin as described in Figure 
1.4. Insulin and free C peptide are packaged in the Golgi into secretory 
granules which accumulate in the cytoplasm. When the β-cells are 
appropriately stimulated, insulin is secreted from the cells by exocytosis and 
diffuses into the islet capillary blood. The C peptide is also secreted into 
blood, but has no known biological activity (Genuth, 1993).  
       1.1.4.3. Regulation of Insulin Secretion 
            Insulin is secreted primarily in response to elevated blood glucose 
concentrations. Elevated glucose concentrations in extracellular fluid lead to 
glucose transport into the β-cells by facilitated diffusion through a glucose 
transporter-2 (Glut-2) (Meglasson and Matschinsky, 1986). Elevated glucose 
within the β-cell causes an increase in the ratio of ATP to ADP that ultimately 
leads to depolarization of the plasma membrane via inhibition of ATP-
sensitive K+ (KATP) channels.
  The subsequent activation of calcium channels  
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                                                                                          (Snustad et al., 1997) 
 
 
Figure 1. 4. The Process of Insulin Biosynthesis 
The preproinsulin contains four sequential peptides including a signal peptide and A, 
B and C chains. After removal of its signal peptide, proinsulin is generated with 
three other peptides: an amino-terminal B chain, a carboxy-terminal A chain and a 
connecting C chain. A chain and B chain are connected by two disulfide bonds. 
Mature insulin is formed by excising the C peptide from proinsulin through specific 
endopeptidases in the endoplasmic reticulum. 
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results in influx of extracellular calcium.  The resulting increase in intracellular 
calcium is thought to be one of the primary triggers for exocytosis of insulin-
containing secretory granules (Deeney et al., 2000; Henquin, 1990). Elevated 
glucose not only stimulates insulin secretion, but also transcription of the 
insulin gene and translation of its mRNA further increases insulin production 
(Evans-Molina et al., 2007). The normal fasting blood glucose concentration 
in humans and most mammals is 80 to 90 mg/100 ml (4 to 5 mM), associated 
with very low levels of insulin secretion. Some neural stimuli (e.g. sight and 
taste of food) and increased blood concentrations of other fuel molecules, 
including amino acids and fatty acids, also promote insulin secretion. 
Stimulation of insulin release is readily observed in animals or people 
(Berthoud et al., 1981; Teff et al., 1991). 
       1.1.4.4. Insulin Action on Cells in the Vasculature 
            Insulin initiates its cellular responses by binding to its cellular receptor, 
a transmembrane, multisubunit glycoprotein that contains insulin-stimulated 
tyrosine kinase activity (Kido et al., 2001). The insulin receptor cDNA was 
cloned (Ebina et al., 1985; Ullrich et al., 1985) and a crystal structure of the 
receptor protein was determined (Hubbard et al., 1994).  The cellular content 
of insulin receptors is variable, with the highest level of expression in cells 
that are most responsive to insulin for glucose, lipid and protein metabolism, 
specificially adipose, skeletal muscle and liver. The abundance of receptor 
mRNA and protein are upregulated with differentiation of adipocyte and 
muscle precursor cells as they obtain an insulin-sensitive phenotype (Sibley 
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et al., 1989). In BC3H1 mouse muscle cell line, exposure to insulin reduces 
receptor mRNA abundance, which may play a role in regulation of receptor 
number in vivo (Mamula et al., 1990). In rare cases of severe insulin 
resistance, due to mutations in the receptor gene, extreme reduction in 
receptor abundance has been shown. However, altered receptor abundance 
is not believed to play a major role in common forms of insulin resistance in 
obesity or type 2 diabetes (Imano et al., 1991). 
            The vasculature is an insulin-responsive tissue. The activation of 
insulin receptors by insulin binding results in diverse signalling processes 
that mediate the many actions of insulin in vascular cells. Glucose uptake 
and metabolism are insulin independent in human micro- and macrovascular 
ECs. The major glucose transporting protein of ECs, however, is the glucose 
transporter-1 (Glut-1) which is not influenced by insulin (Gosmanov et al., 
2006; Pekala et al., 1990). The main physiological role of insulin receptor 
expression in ECs appears to be the rapid and unidirectional transport of 
intact insulin across the endothelial monolayer to insulin-sensitive tissues 
(Bertelsen et al., 2001). Another important effect of insulin in ECs is to evoke 
vasorelaxation through activation and/or increased expression of endothelial 
nitric oxide synthase (eNOS) (Fisslthaler et al., 2003; Wang et al., 2006). As 
a result, elevated blood flow augments delivery of glucose and insulin to 
metabolic insulin target tissues, where both substances directly promote 
glucose uptake (Kim et al., 2006). Actions of insulin include the regulation of 
cell growth, gene expression, and protein synthesis. Studies of cultured 
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vascular smooth muscle cell (VSMC) in the presence of insulin showed 
increasing cell mitogenosis, protein synthesis and production of matrix 
proteins. These changes can result in atherogenesis through VSMC 
hypertrophy and hyperplasia, and ECM protein synthesis (Feener and King, 
1997; Howard et al., 1996). However, endothelial-derived NO can reduce the 
progression of atherosclerosis through inhibiting proliferation of VSMC and 
platelet adhesiveness (Mollace et al., 1991; Moncada et al., 1988; Radomski 
et al., 1987). The ability of insulin to increase production of NO has been 
shown in cultured ECs (Zeng and Quon, 1996). NO is an important 
vasodilator and plays a critical role in the regulation of vascular tone and 
blood pressure (Vallance et al., 1989). In contrast, it has been shown that a 
high dose of insulin increases ET-1 levels in cultured ECs (Ferri et al., 1995b; 
Mandal et al., 2000). Increased ET-1 levels are also found in type 2 diabetic 
subjects in response to hyperinsulinemia (Ferri et al., 1995a; Ferri et al., 
1995b). ET-1 exerts a potent vasoconstrictor effect on the vasculature and 
produces an elevation of systemic blood pressure in anesthetized animals 
(Miller et al., 1989; Yokokawa et al., 1989). Some studies showed that 
hypertensive patients have high ET-1 levels in their plasma (Kohno et al., 
1990; Shichiri et al., 1990) and patients with endothelin dependent malignant 
hemangioendothelioma have hypertension induced by an elevated level of 
plasma ET-1 (Yokokawa et al., 1991). The actions of insulin appear to be 
contrary regarding the production of both NO and ET-1. Reports show the 
ability of insulin to induce vasodilatation is low in insulin resistance and 
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diabetes (Steinberg et al., 1996) which could be due to inactivation of NO or 
the inability of ECs to produce NO (Ting et al., 1996). Thus, insulin may have 
antihypertensive and anti-atherogenic actions at an appropriate physiological 
dose or in the non-diabetic state. 
1.2. Endothelial Dysfunction in Diabetes 
    1.2.1. Endothelium Properties 
            Endothelial cells had long been viewed as passive inert vascular 
lining cells with their primary essential function being the maintenance of 
vessel wall permeability. It is now known however that they play important 
roles in the regulation of vascular tone, coagulation and fibrinolysis, cellular 
growth and differentiation, and immune and inflammatory responses. The 
endothelium, a distributed organ consisting of a monolayer of metabolically 
active ECs lining all blood and lymphatic vessels, is currently viewed as a 
dynamic, heterogeneous, disseminated organ that possesses vital secretory, 
synthetic, metabolic and immunologic functions and plays an important role 
in the structural integrity and normal function of the circulatory system (Aird, 
2004). ECs derived from diverse tissues or vascular sites exert variation in 
the appearance, physiological functions and response to pathological stimuli. 
ECs participate in a large number of physiological processes including the 
control of vasomotor tone, the trafficking of cells and nutrients, the regulation 
of permeability, and the maintenance of blood fluidity. In addition, the 
endothelium mediates new blood vessel formation, contributes to the balance 
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of pro- and anti-inflammatory mediators, and may play a role in antigen 
presentation. In accomplishing these tasks, the endothelium exhibits a 
remarkable "division of labor". For example, arterial endothelium is primarily 
responsible for mediating vasomotor tone; endothelium in postcapillary 
venules regulates leukocyte trafficking; capillary ECs display organ-specific 
barrier properties (e.g. blood brain barrier versus fenestrated, discontinuous 
endothelium in hepatic sinusoids); and ECs from different vascular beds 
balance local hemostasis via the expression of site-specific patterns of 
anticoagulants and procoagulants (Aird, 2001). In recent years, in vivo phage 
display and direct proteome mapping of the intact vasculature have revealed 
a rich diversity in EC surface markers (Arap et al., 2002; Oh et al., 2004). 
            The vascular endothelium has extensive regulatory capacities and 
senses changes in hemodynamic forces and blood borne signals to release a 
number of vasoactive substances which are critical to maintain vascular 
homeostasis. Endothelium acts as a selective permeability barrier for 
substances including H2O, CO2, ions, small lipid molecules, and plasma 
proteins for exchange between the blood and extravascular tissue, 
maintaining the homeostatic balance between the intra- and extra- cellular 
environment. Endothelium plays a role in metabolism by displaying enzymes 
responsible for a number of important biochemical reactions including 
angiotensin-converting enzyme (ACE) which is an ectoenzyme found on the 
luminal surface of the endothelium. One function of ACE is to convert 
angiotensin I to angiotensin II, a vasopressor (Webb and Cockcroft, 1990). 
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ECs normally inhibit platelet adhesion and aggregation by producing PGI2 
and NO. ECs limit activation of the coagulation cascade by the 
thrombomodulin-protein C and the antithrombin III pathway, and regulate 
fibrinolysis by producing tissue plasminogen activator (tPA) and its inhibitor 
PAI-1, and thus maintain blood fluidity (Borsum, 1991; Pearson, 1991). ECs 
secrete multiple vasoactive substances critical in the regulation of vascular 
tone as well as a wide array of cytokines and growth factors such as TGF-β 
and angiotensin II. Endothelium affects VSMC and mensangial cell function 
by producing mediators such as NO and ET-1. ET-1 stimulates contraction 
and proliferation of VSMC and mesangial cells while NO has opposite effects 
(Stehouwer, 1998). 
    1.2.2. Transportation of Glucose in Endothelial Cells  
            Vascular ECs have been described as “glucose-blind”, due to their 
inability to down-regulate the rate of glucose transport when exposed to high 
glucose levels for 24 hours (Kaiser et al., 1993; Sasson et al., 1996). These 
observations suggested that vascular ECs are unique in their inability to 
modify glucose transport when exposed to extracellular high glucose 
concentrations. An unregulated influx of high glucose causes overproduction 
of ROS, which consequently impair vascular EC functions (Creager et al., 
2003; Guzik et al., 2002; Hammes et al., 2003; Milstien and Katusic, 1999). 
In addition, the uptake of D-glucose in ECs occurs via the glucose 
transporter-1(Glut-1), which is not influenced by insulin, in contrast to glucose 
transporter-4 (Glut-4) in muscle cells (Gosmanov et al., 2006). Therefore, 
  
 25 
glucose taken up in ECs reflects the glucose level in the blood independently 
of insulin sensitivity (Bertelsen et al., 2001). In contrast, vascular ECs in 
response to changes in ambient glucose showed reversible regulation of 
Glut-1 expression and their hexose transport system. This suggested that the 
down-regulatory response may protect ECs against deleterious effects of 
increased glucose influx during long-term or chronic hyperglycemic 
conditions (Alpert et al., 2005). Various types of vascular ECs, such as 
macro- and micro-vascular ECs, may respond differently to hyperglycaemic 
conditions. For example, bovine retinal ECs maintained a constant level of 
glucose uptake throughout a 72 hour incubation period at either 5 or 30  mM 
glucose, while bovine brain and rat heart ECs down-regulated glucose 
transport within 24 hours of exposure to 30 mM glucose (Milstien and 
Katusic, 1999). Acute high glucose challenges are harmful to bovine aortic 
ECs due to the inability to down-regulate glucose influx (Alpert et al., 2005). 
The human or porcine aortic ECs treated with high glucose used in our 
present study may be similar to bovine aortic ECs. At 24 hours, human or 
porcine aortic ECs may be impaired by high glucose and could be used as 
an in vitro model for EC injury by hyperglycemia.            
    1.2.3. The Concept of Endothelial Dysfunction 
            The vascular endothelium is not a mere barrier between intravascular 
and interstitial compartments, but a widely spread organ, which is 
responsible for the regulation of hemodynamics, angiogenic vascular 
remodeling, and metabolic, synthetic, inflammatory, antithrombogenic, and 
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prothrombogenic processes. As any other organ, the vascular endothelium is 
a subject for dysregulation, dysfunction, insufficiency, and failure. Endothelial 
dysfunction describes disturbances in the barrier function of the vascular 
endothelium; impaired antithrombogenic properties; perturbed angiogenic 
capacity; inappropriate regulation of vascular smooth muscle tonicity, 
proliferative capacity, and migratory properties; perturbed synthetic functions; 
and prevention of neutrophils and monocytes from diapedesis. The 
endothelium is involved in both the physiological regulation of vascular tone 
and the structural transformation of the vessel under pathological conditions. 
Endothelial dysfunction has been implicated in the pathogenesis and clinical 
course of all known cardiovascular diseases and is associated with future 
risk of adverse cardiovascular events (Schachinger et al., 2000; Suwaidi et 
al., 2000). Under physiological conditions, ECs continuously secrete NO, 
which relaxes VSMCs and ensures vessel patency. Damaged or excessively 
activated ECs can also secrete vasoconstrictor factors, the best known of 
which is ET- l, as well as factors that affect the differentiation and growth of 
VSMCs. ET-1 and other factors are released from ECs into the bloodstream, 
where their chemotactic action can induce leukocytes and platelets to 
migrate to the endothelial wall. The disturbed permeability of the endothelium 
leads to an increased influx of substances including adhesion molecules and 
inflammatory factors from the circulation into the vessel wall. ECs induce 
adhesion by expressing specific surface adhesion molecules such as 
selectins, integrins and a supergene family of immunoglobulins that can 
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interact with ligands on leukocytes and platelets (Bombeli et al., 1998; Joris 
et al., 1983). The expression of adhesion molecules is increased in ECs 
chronically exposed to risk factors for atherosclerosis. In addition, EC 
dysfunction can lead to accelerated intravessel blood coagulation. It is 
evident that the endothelium plays a central role in many of the early 
pathophysiological processes involved in atherosclerosis.  
    1.2.4. Endothelial Dysfunction in Diabetes 
            The vascular endothelium is the initial target site of injury in diabetes. 
The proximate causes of endothelial injury are not known but likely include 
hyperglycemia, exposure to AGEs, activation of PKC, increased expression 
of TGF-β and VEGF, oxidative stress and other components of the insulin 
resistance syndrome which are hyperinsulinaemia, hypertension and 
dyslipidaemia (Stehouwer et al., 1997). These factors probably contribute to 
endothelial dysfunction in human diabetic complications and include the 
following: the endothelium loses its antithrombotic and profibrinolytic nature 
and may instead acquire prothrombotic and antifibrinolytic properties, a 
transition marked by high plasma levels of thrombomodulin and PAI-1. 
Platelet adhesion and aggregation are no longer inhibited but may actually 
be stimulated by prethrombotic factors released from injured ECs, such as 
tissue factor and von Willebrand Factor (vWF) (Stehouwer, 1998). 
Endothelial dysfunction in diabetes mellitus may result from a decreased 
bioavailablity of NO coupled with an exaggerated production of ET-1 (Mather 
et al., 2001a,b). Endothelium-dependent, NO-mediated vasodilatation 
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decreases and VSMC contraction is enhanced so hypertension ensues 
(Elliott et al., 1993). One of the most important forms of endothelial 
dysfunction is BM thickening and an increase in vascular permeability which 
may result from loss of heparan sulfate proteoglycan (HSPG) (Kanwar et al., 
1980). Releasing of bioactive factors from heparan sulfate (HS) chains due to 
HSPG degradation may also be an important mechanism for endothelial 
dysfunction (Kanwar et al., 1980).  
         In diabetes, BM is thickened and altered in composition, likely due to 
enhanced synthesis of matrix proteins by TGF-β activity and inadequate 
counter-regulation of matrix protein synthesis by the defective matrix itself 
(Chen et al., 2001; Wolf et al., 2005). Chondroitin sulfate proteoglycans 
(CSPGs) and dermatan sulfate proteoglycans (DSPGs) are increased while 
HSPGs are markedly reduced in diabetes (Heickendorff et al., 1994). The 
thickness of the glycocalyx, the glycoprotein–polysaccharide, which contains 
large amounts of HSPGs is markedly reduced (Nieuwdorp et al., 2006a,b). 
Loss of the glycocalyx leads to a wide spectrum of vascular abnormalities, 
which include the adhesion of mononuclear cells and platelets to the 
endothelial surface, attenuated NO availability which may cause a 
moderately increased leakage of macromolecules through the endothelium in 
hyperglycemia and diabetes. This phenomenon might be the basis of the 
Steno Hypothesis (Deckert et al., 1989), which proposes that 
microalbuminuria in diabetes reflects a systemic leakage of albumin and 
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atherogenic lipoproteins through the endothelium, thus reflecting an 
enhanced risk for atherothrombosis and cardiovascular disease.  
1.3. Degradation of Heparan Sulfate Proteoglycan (HSPG) in    
       Diabetes 
 
    1.3.1. Definition of Proteoglycans 
            Proteoglycans (PGs) are ubiquitous macromolecules produced by 
most eukaryotic cells, and are found predominantly on the cell surface, in the 
ECM and intracellular granules (Kjellen and Lindahl, 1991). The structure of 
PGs includes a core protein onto which are bound numerous sulfated and/or 
acetylated glycosaminoglycans (GAGs). The core protein is the backbone of 
the PG structure and contains a few or many GAG binding sites. Most 
biological activities attributed to PGs depend on the presence of the core 
protein. The core protein may provide a scaffold for the appropriate 
immobilization and spacing of the attached GAG chains (Brennan et al., 
1983; Hautanen et al., 1989). The core protein assumes an anchoring 
function for attaching the PG core protein to the cell surface, which may be 
essential for the appropriate positioning of a GAG-bound ligand (Marcum et 
al., 1986; Wagner et al., 1989). Anchoring of PGs to the cell surface may be 
a prerequisite for their ability to influence the adhesion of cells to the ECM 
e.g. binding of HS chains to fibronectin exposes the cell binding site of this 
protein and thus promotes the interaction with its integrin receptor 
(Johansson and Hook, 1984; Woods and Couchman, 1988). The core 
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proteins interact with the cell and mediate cell responses such as 
reorganization of the actin cytoskeleton and the formation of focal cell 
adhesions (Bernfield and Sanderson, 1990; Bourin and Lindahl, 1993).  
            GAG chains made up of repeating acetylated and sulfated 
hexosamine and hexuronic acid subunits are organized in patterns which 
impart localized regions of high anionic charge alternating with neutral 
segments (Petitou et al., 1986). The relative arrangement of these charged 
and uncharged areas provides the molecule with additional information 
carrying ability. The unique structural features of PGs endow them with 
properties that may influence a wide range of biological processes. Several 
structurally related GAGs, other than HS, including dermatan sulphate (DS), 
chondroitin sulfate (CS), and hyaluronic acid have been identified in 
association with cell membranes and in the ECM (Hook et al., 1984). HSPGs 
mainly carry HS GAG chains on their core proteins. They can be classified as 
those present on the cell surface, such as syndecans, those anchored to the 
cells surface by glycosyl-phosphatidylinositol (GPI) such as glypican, and 
those present in BM, including perlecan, agrin and collagen type XVIII. Two 
types of HSPG mainly found in vasculature are syndecans expressed on EC 
surface and perlecan in ECM or BM. 
    1.3.2. Heparan Sulfate Proteoglycans (HSPGs) 
            HSPGs play an important role in cell to cell and cell to ECM or BM 
interaction in blood vessels. They are concentrated mostly in the intima, 
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where ECs lie on their BM, and in the inner media which contains ECM and 
several elastic laminae in large vessels. In capillaries, HSPGs are found 
mainly in the subendothelial BM, where they support proliferation and 
migrating ECs and stabilize the structure of the capillary wall. The BM 
contains type IV collagen associated with laminins, entactin and HSPGs. The 
major HSPGs in the cardiovascular system belong to the syndecans, 
glypican, and perlecan core protein families. Syndecans and glypican 
represent the majority of HSPG gene families and are present on the surface 
of mammalian cells. Syndecan core protein is a transmembrane protein and 
carries both HS and CS side chains, whereas the glypican core protein is 
covalently linked to membrane lipids via GPI  anchors and mainly carries HS 
chains (David et al., 1990). Perlecan is the most complicated HSPG and 
carries most of the HS GAG chains. It has a large core protein with five 
domains to which three HS chains are usually attached. It is mainly secreted  
into all BMs and many ECMs and interacts with collagens, laminin, and other 
components (Murdoch et al., 1992). Therefore, HS is the most common GAG 
found on the EC surface and in the ECM and a prominent component of 
blood vessels. 
    1.3.3. HSPG Structures  
       1.3.3.1. Syndecans 
            The syndecan gene family has been classified into four members in 
mammals using molecular biology techniques of cloning of the syndecan 
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core protein and sequencing cDNA-derived amino acid (Bernfield et al., 
1992). The four characterized family members are syndecan-1 (syndecan) 
(Jalkanen et al., 1987), syndecan-2 (fibroglycan) (Marynen et al., 1989), 
sydecan-3 (N-syndecan) (Carey et al., 1992) and syndecan-4 (amphiglycan) 
(David et al., 1992). Syndecan-1 and -3 and syndecan-2 and -4 can be 
considered to form two subfamilies, based on structural comparison of their 
core proteins such as size, GAG attachment site and sequences (Bernfield et 
al., 1992).  Virtually all adhesive cells express at least one syndecan, and 
most express multiple syndecans (Kim et al., 1994). 
            Syndecan family core proteins exhibit very specific distribution among 
different cells, tissues, and at different developmental stages (Kim et al., 
1994). Syndecan-1, -2, and -4 are mainly distributed on ECs and VSMCs at 
vascular basolateral surfaces (Cizmeci-Smith et al., 1992; Kojima et al., 
1992). Syndecan-3 has been characterized as the neural representative of 
the syndecan family, but is also expressed in some stratified epithelia and 
differentiating cartilage cells (Gould et al., 1992).             
            All syndecan core proteins contain different amino acid sequences in 
the extracellular domain (ectodomain) and conserved transmembrane and 
cytoplasmic domains (Bernfield et al., 1999). Syndecans are anchored to 
plasma membranes via a 24-25 amino acid long hydrophobic 
transmembrane domain (Stipp et al., 1994). The conservation of amino acids 
within the transmembrane domain is striking and appears to be the 
conservation of a unique and defined structure with a role in the dimerization 
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or oligomerization of syndecan with itself or possibly with other membrane 
proteins. These domains contain regions for interactions with other 
membrane proteins and for localization to distinct membrane compartments 
and may be sites of signalling or internalization (Lebakken and Rapraeger, 
1996). The cytoplasmic domains are relatively short containing 28-34 amino 
acids. A membrane proximal common region, containing a serine and a 
tyrosine, is strictly conserved among all the family members suggesting a 
sequence-specific function (Rapraeger and Ott, 1998). The common region 
may be the site for formation of cytoplasmic signalling complexes (Fanning 
and Anderson, 1996). The cytoplasmic domain likely interacts with 
evolutionarily stable components such as cytoskeletal actin and tubulins, and 
regulatory proteins calmodulin (Doolittle, 1991). Syndecan ectodomain 
sequences show only limited amino acid sequence similarity. The 
ectodomains are among the most rapidly diverging vertebrate proteins with 
the exception of their regions for GAG attachment, cell interaction, proteolytic 
cleavage, and oligomerization. The ectodomains contain two regions for 
GAG attachment. In syndecan-1 and -3, the GAG attachment sites occur in 
two distinct clusters; one is near the N-terminus and the other near the 
membrane-attachment site, separated by a proline- and threonine-rich 
sequence in the case of syndecan-3. The existence of GAG binding sites in 
syndecan-2 and -4 is only at the distal part (Kokenyesi and Bernfield, 1994). 
One interesting feature common to syndecans is the presence of dibasic 
sequences surrounded by acidic amino acids at the border of the 
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transmembrane domain and ectodomain or within the proximal ectodomain. 
These dibasic sequences are potential protease cleavage sites. The 
selective cleavage of the core protein, known as shedding, is regulated by 
tyrosine kinase, PKC, serine proteases and other signaling pathways 
(Fitzgerald et al., 2000; Jalkanen et al., 1987). Shedding removes the 
ectodomains and their attached polysaccharides as intact PGs from the cell 
surface and releases them into the pericellular or extracellular space. 
Therefore, shedding regulates the amount of HS not only on the cell surface 
but also in the ECM. The intact PGs still retain their ability to bind ECM 
ligands such as basic fibroblast growth factor (bFGF) (Kato et al., 1998). The 
shedding of syndecan-1 and -4 from epithelial cells or ECs is enhanced by 
specific proteases and growth factors such as plasmin, thrombin and 
members of the epidermal growth factor (EGF) family and by cellular stress 
(mechanical, heat shock, hyperosmolarity) acting through the Jun N-terminal 
kinase/stress activated protein kinase (JNK/SAPK) pathway (Jalkanen et al., 
1987; Subramanian et al., 1997). Thrombin and plasmin may cleave at 
mono- or dibasic-sites adjacent to the plasma membrane in the vertebrate 
syndecans (Subramanian et al., 1997). In the case of syndecan-1, the 
shedding of ectodomains from the surfaces of cultured cells is part of normal 
turnover and involves release of the soluble ectodomain (Bernfield et al., 
1992; Jalkanen et al., 1987; Saunders et al., 1989). Shedding of syndecan-1 
was originally shown to be sensitive to tissue inhibitor of metalloproteinase-3 
(TIMP-3) (Fitzgerald et al., 2000; Subramanian et al., 1997) and can be 
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mediated by matrix metalloproteinase-7 (MMP-7) (matrilysin) and membrane-
type matrix metalloproteinase-1 (MT-MMP-1) (Endo et al., 2003; Li et al., 
2002). 
       1.3.3.2. Perlecan 
            Perlecan is one of the most heavily studied PGs and has been found 
in all BMs and many ECMs. Its name is derived from the pearl-like structure 
in rotary-shadowing indicating a variable number of globules separated by a 
thin segment. The sequence of perlecan is known in human and mouse 
(Murdoch et al., 1992; Noonan et al., 1991). The human perlecan gene 
resides on the telomeric region of chromosome 1 and has been localized to 
the 1p36.1 band (Iozzo et al., 1997). The core protein is about 80 nm long 
and contains 5-7 variable-length globular domains (Olsen, 1999). Its 
precursor protein is about 400-470 KDa, and the mature core protein 
appears to have a similar size (Ledbetter et al., 1985). Mammalian perlecan 
core protein contains five domains: one unique domain at the N-terminal 
region and four other domains containing motifs present in other proteins. 
Mammalian perlecan contains a 21 amino acid signal peptide sequence, 
followed by a unique region of domain I. This unique module contains an 
acidic region followed by three Ser-Gly-Asp sequences located in close 
proximity to one another which are the primary HS GAG chain binding sites 
for perlecan. Domain II is homologous to the low-density lipoprotein (LDL) 
receptor and contains a four times repetitive element consisting of six 
cysteine residues spaced over a 40 amino acid region with conserved acidic 
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and hydrophobic amino acids (Noonan et al., 1991). It has been proposed 
that this domain would direct the PG secretion to the basolateral side of the 
BM. Domain III is comprised of modules with homology to the laminin EGF-
like domain and the laminin B domain. One EGF-like module followed by a 
single laminin B domain and three EGF-like modules comprise a structure 
that is repeated three times. The laminin EGF-like modules are rich in 
cysteine residues while the laminin B domain lacks cysteine and has a 
globular structure. Domain III contains a potential GAG binding site, but it is 
unsubstituted (Dolan et al., 1997). It possibly has interactions with cell 
surfaces and/or other components of the BM. Domain IV is comprised solely 
of immunoglobulin IgG repeats. These repeats align with themselves as well 
as with the immunoglobulin repeats of neural cell adhesion molecule (N-
CAM) (Noonan et al., 1991). N-CAM is involved in cell-cell adhesion and can 
bind HS. Domain IV may enable perlecan to form dimers or intracellular 
looping (Inoue et al., 1989). Domain V is the C-terminal of perlecan and 
contains three laminin G domain like modules spaced by two EGF-like 
modules. Domain V has the potential to support GAG attachment due to 
sequences of Ser-Gly-Xxx-Gly and Ser-Gly-Asp/Glu scattered throughout 
this domain (Timpl, 1993). The different perlecan clones have similar 
sequences, however, the sizes of HSPGs in different BMs and cell lines differ 
remarkably. Whether these changes are due to alternative splicing or 
proteolysis in the tissue is unclear at the moment (Klein et al., 1988). Usually 
three HS side chains attach to the N-terminal end of the molecule (Noonan et 
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al., 1991). Occasionally, it may contain both HS and CS chains (Danielson et 
al., 1992). Perlecan derived from ECs contained HS and no CS which is the 
most common forms of this molecule (Iozzo et al., 1994).  
       1.3.3.3. Heparin Serglycin 
            Heparin is expressed in the “basophilic” granules of mast cells which 
are located in connective tissue, near the capillaries and in the walls of blood 
vessels. It is biosynthesized in mast cells as heparin PG containing a unique 
core protein serglycin. The multiple heparin polysaccharide chains are 
covalently attached to the core protein (Robinson et al., 1978). The heparin 
chains are cleaved at random points along the chains to give polydisperse 
mixtures of smaller heparin polysaccharide. The polysaccharides are stored 
in the cytoplasmic secretory granules of mast cells as non-covalent 
complexes with basic proteases and are released as GAGs. Heparin is 
generally described as an anionic polysaccharide or a sulfated GAG with 
irregular sequences. Heparin has a characteristic, anticoagulant property and 
is synthesized in various tissues, especially in the liver, lung, and gut. In the 
kidney, it has been shown that glomerular epithelial cells and ECs have the 
ability to produce heparin-like GAGs (Castellot, Jr. et al., 1985; Castellot, Jr. 
et al., 1986).    
            Although heparin is generally considered a product of mast cells and 
HS is the product of other mammalian cells, heparin and HS have very 
similar disaccharide repeating units and are constructed from the same 
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monosaccharide building blocks. The uronic acid moiety is primarily iduronic 
acid in heparin versus glucouronic acid in HS. The components of heparin 
are more highly sulfated and therefore heparin has a high negative charge 
density, the result of sulfate and carboxylate residues present in the structure 
(Harpel et al., 1996) as described in Figure 1.5. These negative charges on 
the luminal surface of endothelium are thought to play an important role in 
controlling vascular permeability by acting as a “charge barrier” to the 
transvascular movement of the largely anionic plasma proteins such as 
albumin (Hardebo and Kahrstrom, 1985). The disaccharide from heparin 
contains 2.7 sulfate groups on average, compared to 0.6-1 sulfate groups per 
disaccharide from HS (Hileman et al., 1998). There are no distinct 
characteristics to separate heparin and HS based upon their structure.  
    1.3.4. HSPG Biosynthesis 
            During biosynthesis, a series of cytoplasmic enzymes are needed to 
catalyze nucleotide sugars UDP- xylose (Xyl), UDP-Galactose (Gal), UDP-
Glucuronic acid (GlcA), N-acetyl glucosamine (GlcNAc) to form 
polysaccharide chains (Hirschberg et al., 1998). The structure of GAG chains 
depends on the regulated expression and action of multiple 
glycosyltransferases, sulfotransferases, and an epimerase, which are 
arrayed in the lumen of the Golgi apparatus. As shown in Figure 1.6, the    
initial step in the formation of the linkage region is the transfer of Xyl from 
UDP-Xyl to the hydroxyl group of specific serine residues on the core protein 
catalyzed by xylosyltransferase. Then two UDP-Gal and one UDP-GlcA are  
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                                                                                                        (Garg et al., 2000) 
Figure 1.5. Major and Variable Sequences of Original and Fully Sulfated 
Heparin (A) and Heparan Sulfate (B).  
There are more sulfated groups in heparin than heparan sulfate. There are more 
negative charges in the sequences of fully sulfated versus original heparin and 
heparan sulfates 
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added sequentially to the non-reducing end of the growing chain catalyzedby 
their corresponding transferase (Esko and Zhang, 1996). After assembly of 
the linkage region, the GlcNAc and GlcA residues are added alternatively to 
the linkage region tetrasaccharide by GlcNAc/GlcA transferases to form the 
polysaccharide backbone (Duncan et al., 2001). The individual saccharide 
unit is subjected to a series of sequential enzymatic modification reactions in 
which the products of one reaction are substrates for the next. As the HS 
chain is polymerized, it undergoes a series of modifications that include 
GlcNAc N-deacetylation and N-sulfation, C5 epimerization of GlcA to iduronic 
acid (IdoA), and variable O-sulfation at C2 of IdoA and GlcA, at C6 of GlcNAc 
and N-sulf glucosamine (GlcNS) units, and occasionally at C3 of 
glucosamine (GlcN) residue. These modifications involve the enzymes 
GlcNAc N-deacetylase/N-sulfotransferase (NDST), and glucosaminyl 6-O-
sulfotransferases (6OST), and the glucosaminyl 3-O-sulfotransferases 
(3OST) (Liu et al., 1999a; Rosenberg et al., 1997).  
            The majority of GAG chains added to syndecan and perlecan core 
proteins is of the HS type although syndecan-1 and -4 have been shown to 
be modified by CS chains as well (Rapraeger et al., 1985; Shworak et al., 
1994). For syndecan-1 the membrane proximal sites are modified mostly by 
CS and the N-terminal sites are modified predominantly by HS (Kokenyesi 
and Bernfield, 1994). The addition of HS or CS to syndecan-4 is not 
dependent on the specific sites (Shworak et al., 1994). The consensus 
sequence for GAG attachment on the core protein is the amino acid serine 
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followed by a glycine. The structures of the linkage tetrasaccharides 
connecting HS or CS are identical. The GAG-substituted portion of the core 
protein is linked to serine units by a sequence of GlcA-Gal-Gal-Xyl 
tetrasaccharide sequence. Alternatively addition of GlcA or IdoA and GlcNAc 
with various sulfation forms the HS GAG chain while the CS chain is formed 
by adding GlcA or IdoA and N-acetyl galactosamine (GalNAc) with various 
sulfation. The linkage of GlcN and GlcA/IdoA in HS is α1, 4 linkage, while the 
linkage of galactosamine (GalN) and GlcA/IdoA in CS is β1, 3 linkage.  
            The polysaccharide chains of heparin are attached to their core 
protein serglycin via the same GlcA-Gal-Gal-Xyl tetrasaccharide linker as in 
HSPG (Sugahara and Kitagawa, 2000). Biosynthesis of the heparin chains is 
by the same synthesis/modification reactions as HS, but the modifications of 
the [GlcA-GlcNAc]n polymer chains are more localized in HS than in heparin 
(Lindahl, 1989). Transformation of the [GlcA-GlcNAc]n polymer chains to 
heparin begins with replacement of the N-acetyl groups of GlcNAc residues 
with sulfate groups. N-deacetylation and N-sulfation is initiated at random 
sites on the polymer chains, and then continues along the chain from those 
sites until isolated GlcNAc are encountered (Conrad, 1998). The presence of 
isolated GlcNAc residues in heparin is interpreted to indicate they can not be 
a substrate for N-deacetylase. No unsubstituted GlcN residues are found in 
heparin, which suggests that N-deacetylation and N-sulfation is performed in 
vivo. All subsequent modifications depend on N-sulfate groups for substrate 
recognition, thus N-deacetylation and N-sulfation play a key role in 
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determining the fine structure of heparin. Heparin contains less GlcNAc than 
HS, the GlcNAc to GlcNS ratio is approximately 1:4 in heparin vs 1:1 in HS. 
The GlcNAc-containing disaccharides occur in predominantly unmodified NA 
domains (without sulfation), the GlcNS-containing disaccharides in NS 
domains (with sulfation) (see Figure 1.6), with mixed sequences of N-acetyl 
and N-sulf disaccharides separating the two domains. The mixed sequences 
may be functionally significant, as illustrated by the antithrombin-binding 
pentasaccharide, which contains both GlcNAc and GlcNS (Figure 1.6) (Esko 
and Lindahl, 2001). 
    1.3.5. HSPG Biophysiological Functions 
            The core proteins serve as the anchors for polysaccharides on the 
surface of cells determining when and where HS is in a specific tissue. Core 
proteins are also directly involved in HSPG biological functions. Several 
tyrosine and serine phosphorylation sites were identified on the cytoplasmic 
domain of the core protein of syndecan-1 and syndecan-4, suggesting that 
the syndecan core proteins participate in cellular signal transduction 
(Horowitz and Simons, 1998; Ott and Rapraeger, 1998; Volk et al., 1999). 
The structure of the polysaccharides determines the PG ligand binding to 
exhibit biological functions. The extent and sequence of the HS chain 
modifications provide the chain with short stretches having specific binding 
properties such as the pentasaccharide sequence of heparin binding 
antithrombin-III (Lindahl et al., 1984) . Anchoring of HSPGs to the cell  
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                                                                                      (Esko and Lindahl, 2001)    
   Figure 1.6. The Process of Heparan Sulfate Biosynthesis   
Three steps are involved in the heparan sulfate biosynthesis the chain initiation, 
polymerization and modification. The symbols used are defined by the structures 
shown below the scheme. Structural domains (NA, NA/NS, and NS) are defined with 
regard to the distribution of GlcN N-substituents as indicated. Also shown are 
regions that have been implicated in binding of specific ligands, such as FGF-1/FGF-
2 and antithrombin. 
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surface may be a prerequisite for their ability to influence the adhesion of 
cells to the ECM or to other cells. For example, binding of HS to fibronectin 
exposes the site allowing fibronectin to interact with its integrin receptor. 
HSPG has a similar effect on N-CAM of nerve cells (Johansson and Hook, 
1984; Woods and Couchman, 1988). Syndecans on the cell surface are 
believed to be the endogenous receptor for circulating growth factors i.e., 
bFGF, TGF-β, VEGF, hepatocyte growth factor (HGF) and chemokines that 
regulate cell proliferation, differentiation and migration (Linhardt and Toida, 
1997). 
            Perlecan core protein contains individual domains homologous to 
molecules involved in cell proliferation, lipoprotein uptake and cell adhension. 
Each of these domains has exhibited one or more binding sites for a number 
of ligands including BM components (Brown et al., 1997; Hopf et al., 1999; 
Whitelock et al., 1999), cell adhension molecules and growth factors 
(Hayashi et al., 1992; Mongiat et al., 2000; Sharma et al., 1998). LDL 
domains could potentially bind to lipoproteins and may contribute to the 
retention of lipoproteins at the earliest stage of atherosclerosis (Paka et al., 
1999). Interactions between HS chains and laminin may be important for its 
binding in the BM. Perlecan may participate in cell adhesion through 
fibronectin, the appearance of perlecan in the vicinity of adhesion sites in 
cultured fibroblasts supporting this possibility (Singer et al., 1987). It may 
affect differentiation and gene expression through many receptors, in this 
respect resembling laminin, a molecule controlling cell behaviour. Perlecan 
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expression also can be regulated by cytokines and growth factors that are 
responsible for regulating a wide variety of cellular functions including 
embryogenesis, differentiation, migration, proliferation and tumorigenesis. 
Modulation of growth factors, membrane filtering, serving as receptors, and 
cell signalling are some recognized functions of perlecan (Arikawa-Hirasawa 
et al., 1999; Bernfield et al., 1999; Olsen, 1999). 
            The ability of the HS side chains to interact with enzymes such as 
coagulation factors, mast cell proteases, lipoprotein lipase and cytokines 
such as granulocyte macrophage-colony stimulating factor, interferon, 
interleukins also suggests an involvement in the control of normal and 
pathologic processes, such as wound healing, tumor growth and vessel 
formation (Vlodavsky et al., 1993).  Hence, HSPGs play important roles in 
physiological processes of embryonic development, tissue repair, and 
regulation of blood coagulation, cartilage function and glomerular filtration 
(Bernfield et al., 1992; Kjellen et al., 1983; Salmivirta and Jalkanen, 1995). 
Several disease conditions such as cardiovascular diseases, cancer, 
inflammation, diabetes and amyloidosis are associated with changes in the 
expression of PGs as well as with structural and functional alterations of their 
GAG components (Iozzo and Cohen, 1993; Jackson, 1997; Rosenberg et al., 
1997; van der Woude and van Det, 1997). The majority of cell surface 
HSPGs are endocytosed and undergo unique prelysosomal and classic 
lysosomal degradations. Thus, most mammalian cells contain substantial 
amounts of HS degradation intermediates (Yanagishita and Hascall, 1992). 
  
 46 
The processes involved in the metabolic turnover of HSPGs in ECM are 
currently largely unknown. Considering the biological roles of HSPGs in this 
location, i.e., integration of matrix structure, modulation of growth factor 
activities, etc., elucidation of their metabolic regulation poses a very 
interesting question. 
            Heparin is most well known as an anticoagulant and/or antithrombotic 
agent to maintain blood flow in the vasculature through the binding and 
activation of antithrombin III and other mechanisms (Harpel et al., 1996). 
Exogenous heparin is also capable of ameliorating increased vascular 
permeability caused by various polycationic substances including protamine, 
poly-L-lysine or neutrophil cationic protein (NCP) (Fairman et al., 1987; 
Peterson et al., 1987). Heparin is considered as a potent vasodilator that 
most likely lowers elevated blood pressure in hypertensive animal models by 
interacting with vascular endothelial cyclic 3’-5’- guanosine monophosphate 
(cGMP) or releasing endothelial derived NO (Mandal et al., 1995). NO may 
subsequently suppress ET-1 production by a cGMP-dependent pathway 
(Boulanger and Luscher, 1990), decrease VSMC contractility and increase 
vascular wall refractoriness to other vasoconstrictor substances (Mandal et 
al., 1995). The therapeutic action of heparin is ascribed to its anti-
inflammatory properties, including inhibition of blood coagulation, 
complement inactivation, and suppression of leukocyte function (Wardle, 
1996). For example, heparin inhibits leukocyte rolling and adhesion on the 
endothelium (Bazzoni et al., 1993; Ley et al., 1991), and aggregation, 
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degranulation and superoxide anion generation by activated neutrophils 
(Laghi et al., 1984).  Heparin also protects endothelial cells from injury due to 
ROS (Hiebert and Liu, 1990). 
    1.3.6. Analysis of Heparan Sulfate GAGs 
            Unlike other biopolymers such as polynucleotides or polypeptides, HS 
GAGs cannot be amplified because of their structural diversity and complex 
biosynthesis. Since polysaccharides are only available in very small amounts, 
there is no opportunity to sample or study actual cell-surface HS GAG 
sequences that a given protein encounters and binds to in vivo. In addition, 
the heterogeneity and complexity of HS GAGs create significant challenges 
to their purification and characterization of structure–function relationships. 
These limitations have led to the recent development of sensitive analytical 
tools for characterizing small amounts of material. HS can be analyzed in 
terms of disaccharide composition. The disaccharides are distinguished by 
the presence of variable sulfated or nonsulfated GlcA/IdoA and GlcN 
residues. Generally, the basic structural disaccharides of HS appears to be 
quite ancient and the same set of disaccharides exists in most tissues, but 
their relative content varies quantitatively in different species or tissues, or 
ones with different biological activity (Linhardt and Toida, 1997). For example, 
ECs predominantly express the disaccharides of GlcA-GlcNS3S as in the 
connective tissue mast cells and are a critical substructure binding 
antithrombin (Bourin and Lindahl, 1993; Rosenberg et al., 1997), whereas 
kidney HS contains a large amount of IdoA2S-GlcNS3S (Edge and Spiro, 
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1990).  Increasing the sensitivity of detection of HS GAG oligosaccharides 
has been addressed by introducing UV chromophores, and covalent 
derivatization using fluorescent or radioactive tags (Kinoshita and Sugahara, 
1999; Linhardt and Toida, 1997; Vives et al., 1999). Recent advances in 
mass spectrometric methods have enabled detection of picograms to 
femtograms of material without any covalent tags (Juhasz and Biemann, 
1994). The use of matrix-assisted laser desorption/ionization mass 
spectrometry (MALDI-MS) has made it possible to determine the mass of 
sulfated oligosaccharides non-covalently complexed with basic peptides to 
great accuracy (Rhomberg et al., 1998a; Venkataraman et al., 1999). Other 
powerful approaches include combining state-of-the-art separation 
methodology with mass spectrometric technology such as capillary 
electrophoresis mass spectrometry (CE–MS) (Linhardt and Toida, 1999) 
high-performance liquid chromatography (HPLC) (Vives et al., 1999) and 
nanoelectrospray MS (Pope et al., 2001). These analytical tools have been 
applied to dissect the HS GAG oligosaccharide into smaller fragments using 
a series of depolymerizing enzymes and other chemical methods and 
determining the sequence of the oligosaccharides based on specific 
properties of the smaller fragments (Kreuger et al., 2001). Selective enzymes 
and analytical methods that exploit bacterial lyases and lysosomal 
exoenzymes have become available for structural and sequence analysis of 
HS GAGs (Ernst et al., 1998; Rhomberg et al., 1998a; 1998b). Although 
these methods provide excellent sensitivity and facilitate direct identification 
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of the disaccharide on the basis of mass, they do not provide quantitative 
results. There are two significant approaches to sequencing HS GAG 
polysaccharides. In the first methodology, the purified oligosaccharide is 
treated with an exoenzyme that specifically removes a monosaccharide (or a 
sulfate group) from the non-reducing end and the resulting product is 
analyzed by polyacrylamide gel electrophoresis (Turnbull et al., 1999), or 
HPLC (Merry et al., 1999; Vives et al., 1999). The product is subsequently 
treated with other exoenzymes and analyzed in an iterative fashion to read 
the sequence of the HS GAG from the non-reducing end. Although this 
method works very well for most sequences, the lack of exoenzymes to 
remove certain modifications causes problems. For instance, N-sulf 
hexosamines at the non-reducing end cannot be removed in a single step, 
but instead require N-desulfation, followed by chemical reacetylation and 
cleavage by the N-acetyl glucosamidase enzyme. Alternatively, chemical 
methods that clip at the N-sulf glucosamine can be used (such as treatment 
with nitrous acid). Chemical treatments do not specifically remove the 
terminal monosaccharide, but instead attack all such residues randomly, 
resulting in a ladder of multiple products. Unlike protein sequencing, the tools 
for the analysis of HS GAGs are just coming of age and require further in 
depth studies. 
    1.3.7. HSPGs in Vasculature 
            HSPGs are prominent components of blood vessels. In the vascular 
endothelium, HSPG are found both on the cell surface facing the lumen and 
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the underlying BM (Saku and Furthmayr, 1989).  In large vessels, they are 
concentrated mostly in the intima, where ECs lie on their BM, and in the inner 
media which contains ECM including several elastic laminae. In capillaries, 
they are found mainly in the subendothelial BM, where they support 
proliferation and migrating ECs and stabilize the structure of the capillary wall. 
            The ECM is a meshwork-like substance within the extracellular space 
and includes the cell BM. It is composed of a complex mixture of proteins 
many of which are glycoproteins and PGs having carbohydrate chains 
attached to them including HSPGs. These glycoproteins include a wide 
variety of collagens, laminins, fibronectin, thrombospondins and elastins. 
Elastins provide flexibility to arteries, lungs, and skin, while collagen type 1 
and 3, fibronectin and thrombospondins function as scaffolding proteins and 
are involved in matrix signaling by interacting with integrin family of proteins 
and triggering growth-promoting signals. Fibronectin interacting with PGs, 
fibrin/fibrinogen and collagens are important for cell adhesion, growth and 
migration. ECM not only provides structural support to cells and tissues, but 
also plays important roles in regulating the behaviour of cells in multicellular 
organisms. ECM displays a very dynamic equilibrium where there is constant 
synthesis, degradation and reorganization. HSPGs in the BM of the ECM are 
associated with other matrix proteins such as collagen type IV, laminins, 
antactin and fibronectin (Iozzo, 1998; Rops et al., 2004). The PGs promote 
adhesion of the cell to ECM through binding molecules such as fibronectin 
and laminin. HSPGs play an important role in the interaction between cell to 
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cell and cell to ECM or BM. ECs synthesize the constituents of the ECM and 
control vascular permeability to macromolecules by modulating the 
biochemical and biophysical properties of the ECM (Borsum, 1991; Chon et 
al., 1997). HSPGs facing the lumen on the cell surface have been shown to 
be important for extravasation of immune cells during inflammatory reactions 
(Rops et al., 2004; Wang et al., 2005). Reduced HSPG perlecan expression 
was associated with plaque accumulation in human carotid atherosclerotic 
lesions (Tran et al., 2007).     
    1.3.8. HSPG Degradation in Diabetes 
            Changes in arterial PG are seen in both atherosclerosis and diabetes 
(Stevens et al., 1976; Wasty et al., 1993). In both conditions, HS GAG was 
decreased, with the greatest decrease in diabetic patients with 
atherosclerosis (Wasty et al., 1993). The association between 
hyperglycemia, HS, and impaired organ function has been well-studied in 
kidney and other organs, both in patients with diabetes and in animal models, 
where HSPGs are important regulators of glomerular filtration. Perlecan has 
an important role in the maintenance of the glomerular filtration barrier. 
Reduction of HSPG synthesis had been found in glomerular basement 
membrane of both diabetic human and rats and in cultured glomerular 
epithelial cells exposed to high glucose (Brown et al., 1982; Parthasarathy 
and Spiro, 1982; van Det et al., 1996b). Heparinase degradation of kidney 
HS resulted in impaired glomerular filtration of ferritin and albumin (Kanwar et 
al., 1980; Rosenzweig and Kanwar, 1982). It has been shown that the 
  
 52 
biosynthesis of HSPG and HS chain sulfation is decreased in the 
hyperglycemic state. Further studies revealed that the decrease occurs 
specifically in the HS GAG component (Jensen, 1997; Kjellen et al., 1983). 
HS GAGs were decreased in arteries of diabetic patients (Wasty et al., 
1993). HS GAG but not core protein was decreased in cultured ECs and 
kidney cells induced by high glucose (van Det et al., 1996b; Vogl-Willis and 
Edwards, 2004b). Immunofluorescence studies on renal biopsies also 
showed a decrease in staining of HS GAG without changes in core protein 
staining (Tamsma et al., 1994). The content of arterial HS was negatively 
correlated with plasma glucose concentration in diabetic monkeys (Edwards 
et al., 2004). In addition, cultured mesangial and kidney visceral epithelial 
cells have shown a decrease in HSPG when cultured in high glucose (30 
mM) versus control (5 mM glucose) media (van Det et al., 1996b). However, 
it is controversial whether the decrease in GAGs is accompanied by or 
independent of, a decrease in the core protein under hyperglycemic 
conditions in vascular ECs. Changes in GAG content or composition may 
affect the structure and organization of other matrix components. Moreover, 
integrin-linked signalling events may be perturbed, leading to altered cell 
protein expression (Wu and Dedhar, 2001). It has been identified that 
perlecan polymorphism in the GAG-attachment region of domain I is 
associated with diabetic nephropathy (Hansen et al., 1997). The same 
polymorphism in a nondiabetic population was associated with a reduced 
atherogenic lipid risk profile but no decrease in cardiovascular disease  
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suggesting the favourable effect on lipids was counteracted by adverse 
perlecan mediated interactions in the arterial wall (Cai et al., 2000; Vogl-Willis 
and Edwards, 2004a).  
    1.3.9. HSPG Degradation by Heparanase  
       1.3.9.1. Heparanase Expression in Cells 
            Heparanase is an endo-β-D-glucuronidase capable of cleaving 
glycosidic bonds of HS side chains at a limited number of sites by a 
hydrolase mechanism. The degraded HS fragments are still an appreciable 
size (5-7 KDa) (Freeman and Parish, 1998; Vlodavsky and Friedmann, 
2001). This suggests substrate specificity of the enzyme recognizing a 
particular and relatively rare HS structure (Bourin and Lindahl, 1993). A 2-O 
sulfate group on a hexuronic acid residue located two monosaccharide units 
away from the cleavage site appears to be essential for substrate recognition 
by heparanase (Conrad, 1998) as shown in Figure 1.7. Platelets, 
cytotrophoblasts, mast cells, neutrophils, macrophages, and T and B 
lymphocytes express heparanase under normal physiological conditions. 
Platelets have the highest levels of heparanase (Freeman et al., 1999; 
Freeman and Parish, 1998). In fact, serum heparanase is mainly derived 
from activated platelets (Ihrcke et al., 1998). Among various organs, the 
kidney is second to the placenta in heparanase content. Furthermore, 
heparanase is only rarely expressed in human or bovine aortic ECs exposed 
to various physiological activators (Godder et al., 1991; Nakajima et al., 
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                                                                               (Vlodavsky and Friedmann, 2001) 
 
Figure 1.7. Cleavage of HSPG by Heparanase   
Heparanase cleaves HSPGs (arrows) and releases a variety of physiologically and 
pathologically important molecules. Inset shows the heparanase recognition and 
cleavage site. X in sugar unit 4 represents hydrogen or SO3ˉ. 
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1986). Controversially, ECs are able to bind, internalize, and degrade high-Mr 
heparin, and since HS is similar to heparin, this suggests that ECs may 
contain an endoglucosidase that degrades HSPG intracellularly (Barzu et al., 
1987; Godder et al., 1991). Heparanase is also localized to tertiary granules 
of neutrophils and mast cells and is released upon tumor necrosis factor 
(TNF-α) and calcium ionophore treatment (Matzner et al., 1985; Mollinedo et 
al., 1997; Bashkin et al., 1990). Heparanase was released by diapedesis and 
extravasation of a number of immune cells, including neutrophils, 
macrophages, and lymphocytes (Bartlett et al., 1995; Parish et al., 1998; 
Vlodavsky et al., 1992), while heparanase inhibitors exhibited anti-
inflammatory activity (Parish et al., 1998). Cleavage of HS side chains by 
degranulated heparanase during inflammation may facilitate the passage of 
blood-borne normal and malignant cells into tissues by altering the 
composition and structural integrity of the subendothelial ECM (Bartlett et al., 
1995; Vlodavsky et al., 1992; Vlodavsky and Friedmann, 2001). 
       1.3.9.2. Heparanase Properties  
            Recently, partial sequencing of heparanase purified from human 
placenta, platelets, and hepatoma cells led to the cloning of a cDNA and 
gene encoding the heparanase protein (Hulett et al., 1999; Toyoshima and 
Nakajima, 1999; Vlodavsky et al., 1999). The heparanase gene is located on 
human chromosome 4q21.3. The heparanase cDNA contains an open 
reading frame of 1629 bp encoding a 61.2 KDa polypeptide of 543 amino 
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acids. The mature active 50 KDa enzyme has its N-terminus 157 amino acids 
downstream from the initiation codon (Fairbanks et al., 1999; Toyoshima and 
Nakajima, 1999; Vlodavsky et al., 1999) suggesting post-translational 
processing of the heparanase polypeptide at an unusual cleavage site as 
shown in Figure 1.8. 
            Processing and activation occur during incubation of the full-length 65 
KDa recombinant enzyme with several normal and transformed cells and to a 
less extent, with their conditioned medium (Vlodavsky et al., 1999). The 
heparanase precursor may bind to the cell surface, most likely to HS, and is 
then converted to its highly active 50 KDa form in a process accompanied by 
endocytosis of the processed form. This is demonstrated by the observation 
that heparanase activity is readily obtained after transfection of mammalian 
cells with cDNA encoding the entire heparanase precursor (Dempsey et al., 
2000; Vlodavsky et al., 1999).  
       1.3.9.3. Heparanase Functions 
            Heparanase may facilitate the release of a multitude of HS bound 
growth factors, cytokines and chemokines that would enhance the immune 
reaction or activate vascular endothelium (Elkin et al., 2001; Vaday and 
Lider, 2000). HSPGs play a key role in the self-assembly and integrity of the 
multi-molecular architecture of BM and ECMs, hence, their cleavage is likely 
environment. Enzymatic degradation of HS is, therefore, involved in diverse 
fundamental biological and pathological phenomena associated with cell 
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                                                                                                 (Vlodavsky et al., 2001) 
  
Figure 1.8.  Scheme of the Human Heparanase Gene and Protein. 
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migration, including embryonic morphogenesis, angiogenesis, inflammation, 
neurite outgrowth, tissue repair and cancer metastasis (Bandtlow and 
Zimmermann, 2000; Nakajima et al., 1988; Parish et al., 1998; Vlodavsky et 
al., 1992; Wight et al., 1992). Since HSPGs are important constituents of 
blood vessels and the BM, cleavage of HS is expected to facilitate 
extravasation of blood-borne tumor cells, as well as sprouting of angiogenic 
ECs by modulating growth factor activity and bioavailability. Cancer invasion 
and metastasis involves degradation of ECM components, including 
collagens, laminins, fibronectin and HSPGs. The malignant cell is able to 
accomplish this task through the concerted sequential action of enzymes 
such as matrix metalloproteinases (MMPs), serine and cysteine proteases, 
and endoglucosidases. Expression of heparanase is associated with the 
metastatic potential of tumor cells (Hulett et al., 1999; Nakajima et al., 1988; 
Parish et al., 1998; Vlodavsky et al., 1994; Vlodavsky et al., 1999) and 
increased levels of heparanase have been found in sera of animals and 
human cancer patients bearing metastatic tumors (Nakajima et al., 1988). 
Increased heparanase mRNA and heparanase activity has been found in 
high glucose-treated ECs (Han et al., 2007). 
       1.3.9.4. Heparanase and Diabetes 
            Heparanase activity was found in the urine of some diabetic patients 
associated with poor glycemic control (Katz et al., 2002). Although 
heparanase protein was located in both the glomerular mesangial and 
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epithelial cell lysates, there was little or no detectable activity in intact cells 
and their conditioned medium (Katz et al., 2002). This result was confirmed 
by immunohistochemical staining showing the presence of the heparanase 
protein in both the glomeruli and the tubules of normal human and rat kidney 
(Levidiotis et al., 2001).   A decreased intensity of HS staining correlated with 
proteinuria expressed as a function of creatinine clearance (Tamsma et al., 
1994) suggesting alteration of HSPG side chains relevant in the 
pathogenesis of diabetic nephropathy. The abnormalities in HSPG 
metabolism were also observed in the aortic intima of diabetic patients 
suggesting changes in HSPG could occur in both the macro- and micro-
vasculature. Heparanase cleaves HS at specific interchain sites and induces 
loss of the anionic barrier on the luminal surface of endothelium resulting in a 
widespread rise in vascular permeability and vasculopathy. This result was 
determined by observing an increased GBM permeability after perfusion with 
bacterial heparinase (Rosenzweig and Kanwar, 1982).  
1.4. Regulation of HSPG Expression 
    1.4.1. Heparan Sulfate Chain Regulation 
            The regulatory mechanisms for biosynthesis of complex HS GAGs 
differ significantly from those of protein molecules. The latter can be 
regulated primarily by controlling gene transcription and translation 
mechanisms. The regulation of HS GAG biosynthesis comprises many 
cellular functions including the regulation of core protein biosynthesis, 
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multiple glycosyltransferases, sulfotransferases, and epimerase. Each 
regulation requires separate biosynthetic regulation. The localization of 
carbohydrate-synthesizing enzymes in the Golgi apparatus is an important 
factor that would certainly affect the biosynthetic regulation of HSPG (Uhlin-
Hansen and Yanagishita, 1993). Most of the enzymes involved in modifying 
the chain have now been purified and molecularly cloned. The GlcNAc 
NDST, the 6OSTs, and the 3OSTs each represent a gene family whose 
members appear to be expressed in a tissue-specific and developmentally 
regulated pattern. In recent years, there has been a virtual explosion in the 
number of enzyme isoforms identified. There are five 3OSTs, four NDSTs, 
and three 6OSTs identified so far (Aikawa and Esko, 1999; Habuchi et al., 
2000; Kusche-Gullberg et al., 1998; Liu et al., 1999b). Substrate specificity 
studies performed in vitro indicate that the individual members of each 
enzyme subfamily catalyze the same reaction, but in different chemical 
contexts. For example, 3OST-1 is the only 3OST isozyme that can form the 
antithrombin binding sequence (i.e., domains containing GlcA-GlcNS3S). In 
contrast, 3OST-2 transfers sulfate to GlcA2S-GlcNS and IdoA2S-GlcNS, 
whereas 3OST-3A transfers sulfate to IdoA2S-GlcN, where the GlcN has an 
unsubstituted amino group, thus generating the binding site for the viral gD 
glycoprotein (Liu et al., 1999a; Shukla et al., 1999). The three 6OSTs add 
sulfate to the C6 of GlcN units, but the preferred location of the target relative 
to GlcA and IdoA varies (Habuchi et al., 2000). The four NDST isozymes 
show variation in relative ratios of N-deacetylase and N-sulfotransferase 
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activity. Modeling studies of the NDSTs against the crystal structure of the 
sulfotransferase domain of NDST1 (Kakuta et al., 1999) suggest that 
modulations of the binding cleft for the sugar chain may confer different 
substrate specificities for the enzymes (Aikawa et al., 2001). In contrast to 
these sulfotransferases, only one 2-O-sulfotransferase (2OST) (Bai and 
Esko, 1996; Rong et al., 2001) and one epimerase (Crawford et al., 2001; Li 
et al., 2001) appear to exist in vertebrates. A survey of lower organisms has 
shown only single isozymes for the other sulfotransferases, suggesting that 
the ancestral forms of these enzymes perform all the basic reactions of HS 
biosynthesis required to generate the diversity of structure necessary for the 
various biological activities essential to the organisms. A mutation in the 
gene for the IdoA 2OST by insertional mutagenesis causes renal agenesis 
and neonatal lethality in the mutant mice (Rosenberg et al., 1997). Analysis 
of tissues from these animals shows a complete loss of 2-O-sulfated IdoA 
containing disaccharides, consistent with the idea that only one 2OST exists 
(Wilson et al., 2002). 
    1.4.2. Proteoglycan Core Protein Regulation 
            The genetic regulation of core protein and multiple carbohydrate-
synthesizing enzymes is key in the regulation of HSPG biosynthesis. This 
regulation can be primarily controlled by gene transcription and translation 
mechanisms. The regulation of syndecan expression is one of the 
fundamental mechanisms that allow syndecans to perform specific functions 
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in a temporal and spatial manner, and these features may enable these 
HSPGs to function specifically in vivo. Syndecan-1 is expressed on a variety 
of cell types and has been proposed to be regulated at both the mRNA and 
protein levels (Bernfield et al., 1992). For instance, syndecan-1 expression in 
mesenchymal cells is induced at the transcriptional level by platelet derived 
growth factor (PDGF) and angiotensin II (Cizmeci-Smith et al., 1993), the 
antimicrobial peptide PR-39 (Gallo et al., 1994)), and bFGF (Elenius et al., 
1992). Syndecan-1 expression can also be upregulated post-transcriptionally 
in stratifying keratinocytes (Sanderson et al., 1992) and in mesenchymal cells 
during kidney formation (Vainio et al., 1992), and in resident peritoneal 
macrophages (Yeaman and Rapraeger, 1993). Macrophages responding to 
an inflammatory signal in the peritoneal cavity express abundant syndecan-1 
mRNA compared to resident peritoneal macrophages and blood monocytes 
(Hayashida et al., 2006). Despite the expression of abundant syndecan-1 
mRNA, the PG is not detected in elicited macrophages suggesting that this 
transcript is not utilized and the presence of a post-transcriptional block 
(Hayashida et al., 2006). PKA increased exocytosis of intracellular syndecan-
1 and reduced endocytosis of cell surface syndecan-1 which could indicate 
that cell surface syndecan-1 levels are increased post-translationally 
(Hayashida et al., 2006), since PKA has been shown to enhance exocytosis 
(Bouchard et al., 2004; Katsura et al., 1997) and inhibit endocytosis of cell 
surface proteins and increase their cell surface levels (Bradbury and Bridges, 
1992; Salazar and Gonzalez, 2002). Therefore, the molecular mechanisms 
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responsible for syndecan-1 regulation in cells described above may reflect a 
widespread process controlling the expression of this molecule in a variety of 
cell and tissue types.  
            Regulation of perlecan expression has also been examined at the 
transcriptional and translational levels, suggesting a wide range of potential 
mechanisms that can be used to control the presence of perlecan in a 
particular tissue during development or in disease. The SV-40 Large T 
oncogene was found to inhibit transcription of the perlecan gene while 
stimulating the transcription of the actin gene in a SV-40 transformed renal 
cell line (Piedagnel et al., 1994). cAMP and prostaglandins E1 and E2  which 
are known to increase cAMP concentrations, caused a rapid decrease in 
perlecan mRNA and protein levels in rat glomerular epithelial cells while they 
caused an increase in perlecan mRNA in embryonal F9 carcinoma cells 
which are used to study the effects of cell differentiation (Chakravarti et al., 
1993; Ko et al., 1996). These results confirmed that a control mechanism of 
perlecan mRNA regulation is directly responsive to cAMP and a study on 
perlecan’s promoter proposed a putative cAMP transduction element (Iozzo 
et al., 1997). Furthermore, these results also emphasized that the same 
mediator can act on perlecan expression differently. TGF-β was found to 
increase perlecan expression and core protein production in human 
mesangial and synovial cells (Dodge et al., 1995; van Det et al., 1996a). An 
increase in perlecan expression in colon carcinoma cells by TGF-β appeared 
to be at the posttranscriptional level possibly by enhancing perlecan mRNA 
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stability (Dodge et al., 1990). In addition, perlecan may be subject to 
translational regulation through an estrogen-stimulated pathway which is a 
critical step in the attachment of competent blastocysts to the epithelium of 
the uterus (Smith et al., 1997). The studies of glucose regulating perlecan 
expression indicated that the effect of glucose on perlecan occurs at the 
transcriptional and posttranscriptional level (Kasinath et al., 1996; Templeton 
and Fan, 1996). 
    1.4.3. Insulin and HSPG Expression 
            Increased insulin concentration and decreased vasculature sensitivity 
to insulin have been identified as independent risk factors for cardiovascular 
disease in insulin-resistance syndromes and type 2 diabetes (Despres et al., 
1996; Howard et al., 1996). Binding of insulin to insulin receptors results in 
diverse signalling processes that mediate many actions of insulin in vascular 
cells including modulating transcription, altering cell content of numerous 
mRNAs and stimulating cell growth, DNA synthesis, and replication 
(Bornfeldt et al., 1992; Sowers, 1997). 
            Syndecans, the major HSPGs on EC plasma membranes, are 
believed to interact with many bioactive factors including insulin that affect 
cellular physiological and pathological processes. The sequence alignments 
demonstrate a remarkable similarity at the nucleotide level between the 
mouse syndecan and human insulin receptor cDNA sequences (Ebina et al., 
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1985). The similar region between these cDNAs is at the 5’- and 3’- 
untranslated region suggesting that posttranscriptional controls are shared by 
these two molecules (Ratner et al., 1987; Saunders et al., 1989). HSPGs are 
known to bind growth factors such as bFGF on ECs and TGF-β on a variety 
of cell types (Saksela et al., 1988; Segarini and Seyedin, 1988). Since insulin 
is a known growth factor, the sequence similarity between syndecan and the 
insulin receptor cDNA, suggest that syndecans may be the binding site or 
receptor for insulin or, syndecan may compete with the insulin receptor to 
bind insulin. Therefore, the binding function of insulin to HSPG on the cell 
surface may affect cellular behaviour and synthesis of both HS chains and 
core proteins of HSPG.  
    1.4.4. Heparin and HSPG Expression 
            Heparin protects endothelium by increasing its concentration in 
endothelium hundreds to thousands-fold more than in plasma (Hiebert et al., 
1993) and by increasing HS amounts on EC surfaces (Nader et al., 1991). 
Heparin stimulated ECs to synthesize HS with increased sulfated 
disaccharides (Nader et al., 1989). Heparin is protective of cultured ECs 
damaged by exposure to free radicals (Hiebert and Liu, 1990) and able to 
protect HS from degradation by inhibiting heparanase upregulation (Han et 
al., 2007). In addition to EC protection, heparin blunted enhanced actin 
expression in cultured VSMCs treated with high glucose (Mandal et al., 
2000). Heparin inhibits mitogenesis and migration of cultured mesangial cells 
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(Castellot, Jr. et al., 1985) and proliferation of glomerular epithelial cells 
(Adler, 1991; Karlsson and Marklund, 1987). Heparin inhibits induction of 
immediate early genes (Hofer et al., 1996; Miralem et al., 1996) and 
attenuates the expression of potentially injurious mediators in mesangial cells 
(Kitamura et al., 1994). Moreover, heparin and HSPG inhibit apoptosis of 
glomerular mesangial and epithelial cells suggesting that heparin may 
function as a general inhibitor of apoptosis in a wide range of cell 
types (Ishikawa and Kitamura, 1999).  
1.5. Summary 
            Diabetes is a chronic and progressive disease induced by defective 
production or function of insulin that impacts the quality of people’s lives 
worldwide. The cardiovascular complications of diabetes are the leading 
cause of death in people with diabetes. One of the most essential 
characteristics of diabetic complications is EC dysfunction or injury caused 
by hyperglycemia. Since ECs are a unique organ distributed in the inner 
layer of all vessels that regulate vascular bioactivity and function, in diabetes 
EC dysfunction or injury is responsible for retinopathy and nephropathy in 
micro-vessels and atherosclerosis in macro-vessels. The “steno hypothesis” 
raised by Deckert et al., in 1989 suggested that genetic dysregulation of 
HS/GAG production was associated with diabetic cardiovascular 
complications. Based on their hypothesis, HSPG degradation has received 
considerable focus among several proposed mechanisms of endothelial 
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dysfunction in diabetes, particularly in the kidney. Studies on the alteration of 
HSPG derived from ECs will illustrate the mechanism of EC dysfunction or 
injury, and therefore, help us understand the pathological consequences of 
diabetic cardiovascular complications. HSPGs are macromolecules 
containing a core protein with highly negatively charged HS chains attached. 
Two main types of HSPG, synthesized by ECs in the vasculature, are 
syndecans presented on the cell surface and perlecan in the ECM. 
Syndecans are believed to be part of the endogenous receptor for circulating 
growth factors and chemokines that regulate cell proliferation, differentiation 
and migration (Linhardt and Toida, 1997) and may be a prerequisite for the 
ability of ECs to influence the adhesion of cells to the ECM or to other cells.  
The multi-domain perlecan also possesses functions such as modulation of 
growth factors, membrane filtering, serving as a receptor and influences cell 
signalling (Arikawa-Hirasawa et al., 1999; Bernfield et al., 1999; Olsen, 1999). 
Therefore, degradation of HSPG may cause increased vascular permeability 
and damage to the vascular wall due to loss of negative charges, disturbance 
of the functions of bioactive factors and adhesion molecules, and detachment 
of cells from the BM. Evidence from studies of both humans and animals 
demonstrated that the content of HS and HSPG were reduced in glomerular 
and skin BM and in aortic intimas of diabetic patients. HSPG synthesis was 
also reduced in organs of diabetic rats. However, studies on changes in core 
proteins and HS chains of HSPG are not always consistent and remain 
controversial in diabetes. The effect of high glucose on HSPG core protein or 
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HS GAGs is still unknown, particularly, the alteration of HS GAGs in ECs 
under hyperglycemic conditions at the levels of both degradation and 
synthesis. HS chains are believed to be degraded by heparanase (Vlodavsky 
and Friedmann, 2001) which is observed in tissues of diabetic models and 
various cultured cells.  Previous studies localized heparanase protein in both 
glomeruli capillaries and tubular epithelium and detected heparanase activity 
in the urine of diabetic patients (Katz et al., 2002; Shafat et al., 2006).  
Expression of heparanase mRNA and activity was detected in high glucose-
treated ECs (Han et al., 2007). The studies of heparanase expression in 
diabetes have been restricted to diabetic nephropathy. There has been little 
study of heparanase levels associated with other diabetic cardiovascular 
complications or in vascular endothelium injured by hyperglycemia. Although 
induction of heparanase by high glucose is at least partly responsible for HS 
degradation, it is still unknown if changes in core proteins of syndecan or 
perlecan by high glucose are also correlated with heparanase induction.  
            The antithrombotic drug heparin is considered as a potent vasodilator 
(Mandal et al., 1995) and lowers blood pressure in spontaneously 
hypertensive rats (Yokokawa et al., 1994). It has been shown that heparin 
protects endothelium by increasing HS synthesis and reducing ROS 
production. Insulin regulates uptake of glucose into cells and lower blood 
glucose concentration which may reduce toxicity of high glucose in the 
vasculature. The protective effect of heparin and/or insulin on ECs injured by 
high glucose has shown reduced EC intercellular gaps and the inhibition of 
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heparanase upregulation (Mandal et al., 2000; Han et al., 2007). Heparin 
and/or insulin are shown to prevent ECs from heparinase I injury (Han et al., 
2005). Although both heparin and insulin affect the expression of heparanase 
in ECs treated with high glucose, the influence of these two compounds on 
core proteins of syndecans and perlecan in ECs under hyperglycemic 
condition is still a mystery. Heparin and insulin influence HSPGs by different 
mechanisms, but they may collectively or synergistically activate or inactivate 
the gene expression of syndecan, perlecan and heparanase under 
hyperglycemic conditions. 
            Our hypothesis for this study as outlined in Figure 1.9 is that “Gene 
expression and GAG contents of syndecan and perlecan are altered by 
high glucose. The induction of the heparanase gene by high glucose is 
correlated with these alterations. Insulin and heparin will prevent these 
alterations”. 
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Figure 1.9. Outline of the Hypothesis 
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2. OBJECTIVES 
 
            The purpose of this study was to determine if total GAGs and HS 
disaccharides are altered in cultured ECs and medium under hyperglycaemic 
conditions and the effect of insulin and heparin on the GAG alterations.  An 
additional goal was to elucidate the gene expression of core proteins of 
HSPG syndecan and perlecan as well as heparanase in cultured ECs under 
hyperglycaemic conditions and the effect of insulin and/or heparin. In 
addition, the regulatory mechanisms of gene expression for syndecan and 
heparanase was explored. 
The specific objectives are: 
 To determine changes in GAG content in cultured porcine aortic 
endothelial cells (PAECs) and their medium treated with high glucose 
and/or insulin and/or heparin 
 To determine changes in HS disaccharides in PAECs treated with high 
glucose at 24, 48 and 72 hours 
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 To determine gene expression in heparanase, syndecan and perlecan in       
human aortic endothelial cells (HAECs) treated with high glucose and/or 
insulin and/or heparin 
 To determine the mechanism of gene expression of heparanase and 
syndecan treated with high glucose or high glucose plus insulin plus 
heparin 
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3. Changes in Cultured Endothelial Cell      
    Glycosaminoglycans under Hyperglycemic  
    Conditions and the Effect of Insulin and Heparin* 
 
3.1. Abstract 
Background: Heparan sulfate proteoglycans (HSPGs) contain 
glycosaminoglycan (GAG) chains made primarily of heparan sulfate (HS). 
Hyperglycemia in diabetes leads to endothelial injury and nephropathy, 
retinopathy and atherosclerosis. Decreased HSPG may contribute to diabetic 
endothelial injury. Decreased tissue HS in diabetes has been reported, 
however, endothelial HS changes are poorly studied.  
Objective: To determine total GAGs, including HS, in endothelium under 
hyperglycemic conditions and the protective effect of insulin and heparin.  
Methods: Confluent primary porcine aortic endothelial cells (PAECs) were 
divided into control, glucose (30 mM), insulin (0.01 unit/ml) and glucose plus 
insulin treatment groups for 24, 48 and 72 hours. Additionally, PAECs were 
treated with glucose, heparin (0.5 µg/ml) and glucose plus heparin for 72 
hours. GAGs were isolated from cells and medium. GAG concentrations 
were determined by the carbazole assay and agarose gel electrophoresis. 
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Results: GAGs were significantly increased only in control and glucose plus 
insulin groups at 72 versus 24 hours. Glucose decreased cell GAGs and 
increased medium GAGs, and insulin alone decreased cell GAGs at all times 
compared to control.  In the glucose plus insulin group, cell GAGs were less 
than control at 24 hours, and greater than glucose or insulin alone at 48 and 
72 hours while GAGs in medium were greater than control at all times and 
glucose at 72 hours. Heparin increased GAGs in glucose-treated cells and 
medium. 
Conclusions: High glucose and insulin alone reduces endothelial GAGs. In 
hyperglycemic conditions, heparin or insulin preserves GAGs which may 
protect cells from injury. Insulin is an effective diabetic therapy since it not 
only lowers blood glucose, but protects endothelium. 
* Published in Cardiovascular Diabetology 2009 8:46. 
3.2. Introduction 
            A GAG is a linear, highly negatively charged, heteropolysaccharide 
macromolecule possessing a characteristic disaccharide repeat sequence 
which usually comprises an amino sugar with D-glucosamine or 
galactosamine and a uronic acid residue of either D-glucuronic acid or 
iduronic acid. Based on the composition of disaccharides, GAG structures 
are categorized into six common types including CS, DS, HS, keratan sulfate 
(KS), hyaluronic acid, and heparin. The GAG chain is covalently attached to 
a core protein through an O-link to serine or an N-link to an asparagine 
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residue and this structure is called a proteoglycan. Proteoglycans are 
expressed by all mammalian cells and are found on the cell surface, in the 
ECM and intracellular granules (Kjellen and Lindahl, 1991).  
            HS is a prominent component of blood vessels and the most common 
GAG found on the EC surface and in the ECM. HSPGs are believed to be 
the endogenous receptors for circulating growth factors and chemokines that 
regulate cell proliferation, differentiation and migration (Linhardt and Toida, 
1997). The interaction of HS side chains with bioactive factors controls 
physiological processes of embryonic development, tissue repair, blood 
coagulation, cartilage function and glomerular filtration (Bernfield et al., 1992; 
Kjellen and Lindahl, 1991; Salmivirta and Jalkanen, 1995), and pathological 
processes of wound healing, vessel formation, and tumor cell growth, 
adhesion, invasiveness and metastasis (Vlodavsky et al., 1993). HS 
degradation is considered to be a major cause of endothelial dysfunction 
resulting in disturbance of vascular integrity and barrier properties, due to 
decreased negative charge and increased permeability, and release of 
bioactive substances such as cytokines, enzymes and growth factors bFGF 
and TGF-β. Changes in the expression of proteoglycans, as well as structural 
and functional alterations of their GAG components, are associated with 
cardiovascular disease, cancer, inflammation, amyloidosis and diabetes 
(Iozzo and Cohen, 1993; Jackson, 1997; Rosenberg et al., 1997; van der 
Woude and van Det, 1997). 
  
 76 
            Several studies suggest that HS degradation is associated with 
diabetic nephropathy (van den Hoven et al., 2006; Vernier et al., 1983). An 
increased glomerular albumin filtration rate was observed in 
microalbuminuric patients with overt diabetes (Deckert et al., 1989). 
Increased glomerular basement membrane (GBM) permeability was 
associated with diminished GBM HS content (Vernier et al., 1983). Similar 
changes in HS content were observed in aortic intimas of diabetic patients 
(Wasty et al., 1993). HS in skin basement membrane in patients with diabetic 
nephropathy was also significantly reduced compared to diabetic patients 
without nephropathy. Similarly, reduced 35S-labeled HSPG synthesis was 
observed in aorta, liver and intestinal epithelium of diabetic rats (Brown et al., 
1982; Kjellen et al., 1983; Levy et al., 1984). This evidence suggests that 
changes in HS metabolism could occur not only in the kidney, but also in any 
tissue or organ in the diabetic condition, indicating a link between HS 
abnormalities and vascular complications both in the micro and macro 
vasculature. In addition, heparanase, an endoglucuronidase produced by 
ECs induced by high glucose, could be responsible for the cleavage of HS 
chains (Han et al., 2007). Heparanase activity was increased in the urine of 
diabetic patients (Katz et al., 2002) and reduction of HS moieties in the 
glomeruli of patients with overt diabetic nephropathy in type 2 diabetes was 
correlated with heparanase upregulation (van den Hoven et al., 2006). 
However, specific changes in GAGs from ECs under hyperglycemic 
conditions are not well studied. The purpose of this study was to use primary 
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porcine aortic ECs (PAECs) under high glucose conditions, as an in vitro 
model to determine if changes in GAGs are seen with hyperglycemia. Since 
the hormone insulin regulates glucose metabolism and promotes glucose 
uptake and utilization to reduce glucose concentration in hyperglycemia, we 
also wished to determine the effect of insulin on GAG alteration. Since our 
previous studies showed that heparin also protected ECs from high glucose 
injury (Han et al., 2005), the effect of heparin was also studied. 
3.3. Materials and Methods 
    3.3.1. Porcine Aortic Endothelial Cell (PAEC) Culture 
            Primary PAECs were cultured by the method of Gotlieb and Spector 
(Gotlieb and Spector, 1981). Porcine aortic segments obtained from local 
abattoirs were washed three times in Ca2+-Mg2+-free Dulbecco’s phosphate-
buffered saline (CMF-DPBS) and connective tissue was trimmed from the 
adventitial surface. The aorta was held upright by clamping one end with 
hemostats. The aortic lumen was rinsed three times with CMF-DPBS and 
then filled with collagenase (Type IV, SIGMA, St. Louis, MO, USA; 1 mg/ml in 
CMF-DPBS) for six minutes. After removing the collagenase, the lumen was 
gently rinsed with medium (M199 containing 5.5 mM D-glucose, without 
heparin or insulin, GibcoBRL, Life Technologies, Inc., Grand Island, NY, 
USA) supplemented with 5% fetal bovine serum (FBS, GibcoBRL), 50 µg/ml 
penicillin (SIGMA) and 10 µg/ml streptomycin (SIGMA). The medium with 
cells was plated onto 60 mm culture dishes which were then incubated at 
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37°C with 5% CO2/95% air in a humidified environment. PAECs were 
identified by their morphological appearance of cobblestone-like flattened 
cells, and the presence of von Willebrand factor (vWF) in initial cultures. Non-
endothelial-like cells, such as smooth muscle cells and fibroblasts were 
destroyed cell by cell using a pasteur pipette and mechanical suction before 
the first passage. To pass cells, confluent cultures were washed twice with 
CMF-DPBS and cells were detached by trypsin (0.025% with EDTA in CMF-
DPBS) for two or three minutes at room temperature. The cells were 
resuspended in medium and transferred to 60 mm dishes for further 
passage. For experiments, the cells were grown in 60 or 100 mm dishes at 
passage four. 
    3.3.2. Treatment of Cultures 
            PAECs were grown in 100 mm culture dishes (surface area 78.5 cm2 
/dish) with an estimated 6 million cells/dish at confluence. Cells were 
incubated with four different treatments (3 dishes/group) including control 
(serum free medium), high glucose (30 mM), insulin (0.01 unit/ml), or high 
glucose plus insulin in serum-free medium for 24, 48 and 72 hours. In a 
separate experiment ECs in 100 mm dishes were treated with high glucose 
(30 mM), and/or heparin (0.5 µg/ml), or serum free medium (control) with one 
dish/group for 72 hours. Additionally, PAECs were grown in 60 mm dishes 
and treated as controls or with high glucose for 24, 48 and 72 hours with 3 
dishes/group. After the specified time interval, cell medium was collected into 
15 ml centrifuge tubes. Cells were scraped from the dish using a cell scraper, 
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the dish was washed with DPBS, and cells and washings were collected into 
a 1.5 ml tube and centrifuged to pellet cells. The cell pellets and medium 
were frozen at - 80 °C. Samples were freeze-dried before they were 
analyzed. 
    3.3.3. Extraction of Total GAGs 
            Medium and cell pellets were digested by pronase (0.2 mg/ml in 0.1 
M Tris buffer containing 0.1 M CaCl2, pH 8.0) for 24 hours at 37 °C.  Then 
the digested samples were freeze-dried a second time. Total GAG extraction 
was performed using Vivapure Ion Exchange Mini Spin Columns 
(Vivascience, Germany). Urea buffer (8 M urea with 2% w/v CHAPS (3-[(3-
Cholamidopropyl) dimethylammonio]-1-propanesulfonate), 500 μl, was added 
to the samples which were then triturated with a pipette to insure 
homogenization. The samples were then centrifuged at 5000 x g for 5 
minutes to remove the precipitate.  The supernatant was added into the Spin 
Columns which had previously been equilibrated with 500 μl urea buffer 
followed by centrifugation. The columns with supernatant were centrifuged at 
5000 x g for 10 minutes to remove the flow-through.  Columns were washed 
once with 500 μl of urea buffer. Then columns were washed five times with 
500 μl of 200 mM NaCl, after which total GAGs were eluted with 3 x 100 μl of 
16% NaCl. To precipitate the total GAGs, 1.2 ml of methanol was added to 
the sample, making the final methanol concentration 80% of volume, and 
chilled overnight at 4 °C. The total GAG fraction was collected by 
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centrifugation at 2500 x g for 15 minutes. The resulting precipitate was 
dissolved in 100 μl of distilled water.  
    3.3.4. Determination of total GAGs by the Carbazole Assay 
            The carbazole assay was used to examine the total GAGs isolated 
from cultured PAECs and medium in experiments where cultures were 
treated with high glucose and/or insulin. Briefly, 25 μl of the extracted GAG 
was added to 150 μl of reagent A (25 mM Na2B4O7 in concentrated H2SO4) 
which was heated at 100 °C for 10 minutes. After the reaction was cooled on 
ice, 5 μl of reagent B (carbazole 1.25 g in 1 L 100% ethanol) was added to 
the reaction which was heated at 100 °C for another 15 minutes. The 
absorbance was read by spectrometry at 525 nm using a 96-well micro titer 
plate. The concentrations of GAGs were calculated by comparing to a 
standard curve made with heparan sulfate from porcine intestinal mucosa 
(SIGMA). 
    3.3.5. Gel Electrophoresis Analysis of GAGs 
            Agarose gel electrophoresis described by Jaques (Jaques et al., 
1990) was used to identify GAGs recovered from control ECs and ECs 
treated with glucose, insulin and glucose plus insulin for 72 hours, and with 
glucose, heparin and glucose plus heparin for 24 hours. Total GAGs were 
extracted from cells and medium as describe above. Then 3-5 µl distilled 
water was added to each dried GAG sample and 2 µl of the dissolved GAG 
was added to the lanes on the agarose (1%) gel electrophoresis slide. Slides 
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were run in barbital buffer (pH 8.6) for 20 minutes. Slides were then fixed in 
0.01% (w/v) cetavlon for at least 2 hours. After drying, slides were stained 
with 0.04% (w/v) Toluidine Blue in 80% acetone and background colour was 
removed with 1% acetic acid. HS was identified and visualized by comparing 
to reference HS from porcine intestinal mucosa (0.1 µg/µl, SIGMA).  
    3.3.6. Determination of Total HS Disaccharides  
                in Cells and  Medium 
            Additional experiments were performed for determination of HS 
disaccharides in cells and medium. Total GAGs from three 60 mm dishes 
were combined in order to obtain enough material for HS disaccharide 
analysis by HPLC. Freeze-dried total GAG extracts were dissolved in 20 μl of 
0.2 M Tris-HCl buffer (pH 8.0), then 2 μl of Chondroitinase ACII (0.05 unit/μl) 
and 10 μl of Chondroitinase ABC (0.01 unit/μl) were added to the samples 
which were incubated at 37 °C overnight. Microcon YM-3, 3000 NMWL 
Centrifugal Filter Devices (Millipore, USA) were used to obtain HS 
disaccharides. First, the device was washed with 0.1 M NaOH once followed 
by washing with 50 μl H2O four to five times until the pH of the flow-through 
was neutral. Second, the chondroitinase digested samples were transferred 
to the devices and centrifuged at 10,000 x g for 25 minutes to remove 
chondroitin sulfates. After the devices were washed with double distilled (DD) 
H2O three to four times, the inserts were removed and put into a new 
collecting tube. A mixture of 10 μl of heparinase I (0.3 unit), heparinase II (0.1 
unit) and heparinase III (0.1 unit) in 6 mM NaCl and 3 mM Na3PO4 buffer (pH 
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7.1) were added to the column. After incubation at 37 °C for 24 hours to 
digest HS, the samples were centrifuged at 10,000 x g for 10 minutes to 
remove the buffer. Then HS disaccharides were eluted by three to four 
additions of 50 μl DD H2O. The elution was freeze-dried and then dissolved 
in 15 μl DD H2O. Then 10 μl of the sample was analyzed by HPLC. 
The analysis was performed on a post-column fluorescence RPIP- 
HPLC using Shimazu LC-10Ai system equipped with a RF535 fluorescence 
HPLC monitor and an analytical C18 column (5 μm, 4.6 × 250 mm). The 
mobile phase was A: 8% acetonitrile, 3 mM tributylamine acetate, pH 5.0; B: 
8% acetonitrile, 3 mM tributylamine acetate, 0.2 M NaCl, pH 5.0 with a step 
linear gradient 0-15 min, B 0-30%; 15-30 min, B 30-100%; 30-50 min, B 
100% at a flow rate of 1.0 ml/min. Column temperature was 55 °C. Post-
column reaction reagents were C: 1% 2-cyanoacetamite and D: 0.75 M 
NaOH with a flow rate at 0.2 ml/min. The reaction temperature was 120 °C 
and detected with Ex 346 nm, Em 410 nm. 
    3.3.7. Statistical Analysis 
            Data for total GAGs analysed by the carbazole assay are expressed 
as mean +/- standard error (SE) from three dishes per group. A one-way 
ANOVA was used to determine significant differences between groups. 
Values of P<0.05 were considered to be statistically significant. A one-tailed 
t-test was used to determine significant differences between total GAGs at 24 
and 72 hour. 
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3.4. Results 
    3.4.1. Total GAGs in Cultures  
            Total GAGs were extracted from cells and medium grown in 100 mm 
dishes after 24, 48 and 72 hour treatment with glucose (30 mM) and/or 
insulin (0.01 unit/ml).  
            24 hours: The GAG concentration was significantly decreased in 
high glucose or insulin treated cells compared to control (Figure 3.1.A). 
When high glucose was present, insulin significantly increased GAG 
concentrations in cells compared to insulin alone, although concentrations 
were still significantly less than control cells. In medium from the same 
cultures, GAG concentrations were significantly increased in high glucose 
and decreased with insulin treatment compared to control. GAG 
concentrations in medium were significantly increased by glucose plus insulin 
compared to control and insulin alone treated cultures. When the ratio of 
GAGs in cells and medium was expressed as a percentage, there were more 
GAGs in cells than medium in control and insulin alone treated cultures, 
while in high glucose-treated cultures with and without insulin the ratio was 
reversed (Figure 3.1.B). The percentage of total GAGs in glucose-treated 
cells was significantly lower than control and with insulin alone. The 
percentage of total GAGs in high glucose-treated medium with and without 
insulin was significantly increased compared to control and insulin alone.  
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Figure 3.1.  GAGs from Cultured Endothelial Cells and Medium at 24 Hours 
Cells were treated with high glucose (30 mM) and/or insulin (0.01 unit/ml) for 24 
hours. Total GAGs were isolated from cells (white bar) and medium (grey bar) and 
determined by the carbazole assay (3 dishes/group). Data were analyzed by a one-
way ANOVA. Significantly different than: a, Control; b, Glucose; c, Insulin. p<0.05 
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            48 hours: GAG concentrations in cells were significantly decreased 
in high glucose or insulin treated compared to control cultures. Total GAGs in 
insulin treated cells when high glucose was present was significantly greater 
than high glucose or insulin alone and similar to control cells (Figure 3.2.A). 
In the same cultures GAG concentration in medium was significantly 
increased in high glucose and high glucose plus insulin treated compared to 
control cultures. When GAG percentages were calculated more GAGs were 
found in medium than cells for all groups. The percentage of total GAGs in 
cells was decreased in all treatments compared to controls and increased in 
insulin plus high glucose compared to high glucose or insulin alone (Figure 
3.2.B). The percentages of total GAGs in medium were increased in all 
treatment groups compared to control and decreased in high glucose plus 
insulin treated cultures compared to high glucose and insulin alone.  
            72 hours: Relative GAG concentrations in cells were similar to those 
seen at 24 hour and significantly less than control for all treatment groups. 
High glucose plus insulin significantly increased GAG concentrations 
compared to high glucose or insulin alone (Figure 3.3.A). The GAG 
concentrations in medium were increased in glucose plus insulin treated 
cultures compared to the other three groups. When GAG percentages in 
cells and medium were calculated more GAGs were found in medium than 
cells for all groups while in controls the cells contained most of the GAGs. 
The percentage of total GAGs significantly decreased in cells and increased 
in medium for all treatments compared to control (Figure 3.3.B).  
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  Figure 3.2.  GAGs from Cultured Endothelial Cells and Medium at 48 Hours 
Cells were treated with high glucose (30 mM) and/or insulin (0.01 unit/ml) for 48 
hours. Total GAGs were isolated from cells (white bar) and medium (grey bar) and 
determined by the carbazole assay (3 dishes/group). Data were analyzed by a one-
way ANOVA. Significantly different than: a, Control; b, Glucose; c, Insulin. p<0.05  
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Figure 3.3.  GAGs from Cultured Endothelial Cells and Medium at 72 Hours 
 
Cells were treated with high glucose (30 mM) and/or insulin (0.01 unit/ml) for 72 hours. 
Total GAGs were isolated from cells (white bar) and medium (grey bar) and 
determined by the carbazole assay (3 dishes/group). Data were analyzed by a one-way 
ANOVA. Significantly different than: a, Control; b, Glucose; c, Insulin. p<0.05 
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    3.4.2. Comparison of Total GAGs in Cultures at Different Times   
            GAG concentrations were significantly increased in control cells and 
in control and glucose plus insulin treated medium at 72 compared to 24 
hours. GAG concentrations in control cells at 72 hours were greater than 
high glucose and insulin alone treated cells at 72 hours. GAG concentrations 
in glucose plus insulin treated medium were greater than all other treatment 
groups at 72 hours (Figure 3.4.A and B). Significantly more GAGs were 
found in cells plus medium in control and high glucose plus insulin treated 
cultures at 72 compared to 24 hours and to other groups at 72 hours (Figure 
3.4.C). However, cell GAGs in control and glucose and/or insulin treatment at 
48 hours were decreased compared to both 24 and 72 hours. 
    3.4.3. GAG Analysis by Gel Electrophoresis 
            In order to better define GAGs extracted from cells treated with high 
glucose and/or insulin for 72 hours, GAGs were exposed to agarose gel 
electrophoresis, as shown in Figure 3.5.  In agreement with the carbazole 
assay at 72 hours, control cells showed a higher GAG content then medium, 
while with glucose treatment there were less GAGs in cells then medium. 
Glucose plus insulin treatment showed a greater GAG content than insulin 
treatment alone both in cells and medium. In insulin alone treated cultures, 
the faster migrating component was reduced in cells compared to control and 
high glucose-treated cells. Since heparin interferes with HS determination in 
HPLC and the carbazole assay, GAGs extracted from cells treated with high  
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Figure 3.4. Total GAGs Increased with Culture Time in Both Cells and Medium 
Cells were treated with high glucose (30 mM), insulin (0.01 unit/ml), 
glucose+insulin and control medium for 24, 48, 72 hours (3 dishes/group). GAGs 
isolated from cells (A), medium (B) and cells+medium (C) and determined by the 
carbazole assay are shown. A one-tailed t-test was used to determine significant 
differences between treatment at 24 and 72 hour. Significantly greater than: a, same 
group at 24 hours; b, glucose at 72 hours; c, insulin at 72 hours; d, glucose+insulin at 
72 hours; e, control at 72 hours. p<0.05 
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Figure 3.5. Gel Electrophoresis Showing GAGs in Cells and Medium Treated 
with Glucose and/or Insulin for 72 Hours 
Cells were treated with high glucose (30 mM) and/or insulin (0.01 unit/ml) for 72 
hours. Total GAGs were isolated from cells and medium and visulized by agarose gel 
electrophoresis (3 dishes combined/group). +/- indicates charge direction of migration 
of samples. 
Lanes: S, standard, heparan sulfate from porcine intestinal mucosa; C, control; G, 
glucose; I, insulin; G+I, glucose+insulin  
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glucose and/or heparin for 72 hours were only determined and distinguished 
on gel electrophoresis, as shown in Figure 3.6. Control and glucose-treated 
cells showed results similar to those mentioned above for glucose and/or 
insulin treatment.  Glucose plus heparin had more GAG content in cells 
compared to glucose or heparin alone and in medium compared to heparin 
alone. In medium the fast migrating band was greatest for heparin plus 
glucose treatment while the slower migrating bands were greater for the 
treated group than control. 
    3.4.4. Correlation of Total HS Disaccharides and Total GAGs 
            Control cells and cells treated with high glucose (30 mM) (three 60 
mm dishes/group) were cultured for 24, 48 and 72 hours. Total GAGs and 
HS disaccharides were obtained from the same samples. There was a good 
correlation between total HS disaccharides and total GAGs obtained (Figure 
3.7).  
3.5. Discussion  
            Syndecans and perlecan are major HSPGs synthesized and secreted 
by ECs. Syndecans are mainly expressed on the cell surface and perlecan is 
presented in the ECM (Kaji et al., 2000). HS chains derived from HSPG are 
the main GAGs found in ECs (Gharagozlian et al., 2006). In the present 
study, we found that total HS determined by HPLC correlated well with total 
GAGs determined by the carbazole assay (Figure 3.7). Therefore, total  
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Figure 3. 6.  Gel Electrophoresis Showing GAGs in Cells and Medium Treated 
with Glucose and/or Heparin for 72 Hours 
Cells were treated with high glucose (30 mM) and/or heparin (0.5 µg/ml) for 72 hours. 
Total GAGs were isolated from cells and medium and visulized by agarose gel 
electrophoresis (1 dish/group). +/- indicates charge direction of migration of samples. 
Lanes: S, standard, heparan sulfate from porcine intestinal mucosa; C, control; G, 
glucose; H, heparin; G+I, glucose+heparin  
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Figure 3. 7. Correlation of Total HS Disaccharides and Total GAGs in Cultured 
Endothelial Cells  
Control cells and cells treated with high glucose (30 mM) were cultured for 24, 48 and 
72 hours (3 dishes/group). Total GAGs were isolated, after combining the cells and 
medium separately from the three dishes, and were determined by the carbazole assay. 
HS disaccharides were obtained by heparinase digestion and determined by RPIP-
HPLC systems 
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GAGs likely reflect total HS present within endothelium. The GAGs were 
extracted from the entire cultured endothelial monolayer including mainly 
syndecans and perlecan.  
            Total GAGs from the cells and medium were determined when 
cultured ECs were exposed to high glucose and/or insulin. At the earliest 
observed time (24 hours), cells treated with high glucose showed a reduction 
in total GAGs (Figure 3.1). The observation that cell total GAGs decreased 
and medium GAGs increased up to 72 hours with high glucose treatment 
(Figure 3.3, 3.4, and 3.5) are consistent with the finding that GAG contents 
from syndecan-1 and perlecan were decreased in cultured primary ECs 
treated with high glucose for two and five days (Vogl-Willis and Edwards, 
2004a; Vogl-Willis and Edwards, 2004b). Decreased cell GAGs suggest 
hyperglycemia could induce HSPG degradation or inhibit HSPG synthesis in 
ECs. The possible consequences of decreased GAGs are reduced 
interaction of several biofactors such as growth factors, coagulation factors, 
chemokines, adhesion molecules, and lipoprotein lipase with HSPG in the 
vasculature (Nugent and Iozzo, 2000). Loss of these biofactors is likely to 
induce endothelial injury. We previously observed endothelial injury following 
addition of high glucose in the same culture model (Han et al., 2005). 
Although our culture model uses aortic ECs, and ECs in macro- and micro-
vessels have different properties, both are characterized by the same 
pathological features in diabetes mellitus. Endothelial injury likely contributes 
to diabetic cardiovascular complications both in micro- and macro-vessels 
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such as nephropathy, retinopathy and atherosclerosis (Colwell and Lopes-
Virella, 1988a; Richardson et al., 1980).  
            Increased total GAGs in medium with high glucose treatment suggest 
that GAGs are released from cell proteoglycan core proteins. The core 
protein may remain on the cell surface. This was indirectly confirmed by 
immunoprecipitation assays where the core protein of syndecan-1 remained 
on ECs and was expressed at lower intensity in medium from high glucose-
treated ECs (Gharagozlian et al., 2006). Similarly, immunostaining studies 
showed that reduction in HS GAGs in the GBM under diabetic conditions was 
not accompanied by a reduction in the HSPG core protein (Tamsma et al., 
1994). As well, decreased HSPG synthesis by human aortic ECs in high 
glucose conditions was not the result of a decrease in GAG size, further 
suggesting that entire GAG chains were released into culture medium (Vogl-
Willis and Edwards, 2004a). It is unlikely that GAGs are further degraded in 
medium.  
            Insulin controls blood glucose utilization and influences the 
metabolism of fat and protein. Insulin also has effects on the expression of 
numerous genes. Insulin alone decreased GAG concentration in cells at all 
time points in our study. In a study of regulation of HSPG metabolism and 
hepatocyte growth by insulin and phosphatidylinositol, insulin markedly 
stimulated the rate of internalization of matrix HSPG and phospholipase C 
and therefore may control cell surface HSPG turnover (Ishihara et al., 1987). 
Thus, insulin may regulate enzymes involved in metabolism of proteoglycans. 
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Insulin promoted shedding of syndecan ectodomains from 3T3-L1 adipocytes, 
by an unknown mechanism (Reizes et al., 2006). However, it is unknown 
whether these changes are coordinated by phosphatidylinositol, the second 
messenger in the action of binding insulin to its receptor, and whether 
shedding of syndecans are seen in ECs in response to insulin. In our studies 
there was a trend that insulin alone increased GAGs in culture medium as 
culturing time increased (Figure 3.4) which may indicate HSPG turnover or 
shedding of syndecan into medium, however, GAGs were significantly 
reduced in 72 hour cultures compared to control suggesting that GAG 
synthesis may also be inhibited. These limited observations cannot define 
the precise mechanisms involved in insulin reduction of GAGs in cultured 
ECs, and further investigation is required. Considerable evidence indicates 
that vascular endothelium is a physiological target of insulin and a potential 
link between insulin resistance and atherosclerosis (Hsueh and Law, 1999; 
Mather et al., 2001a). Endothelial dysfunction is one of the earliest detectable 
signs in insulin resistance (Zeng et al., 2000). Our present study shows that 
decreased GAG content in insulin alone treated cells may lead to endothelial 
dysfunction caused by GAG degradation and/or inhibition of GAG synthesis.  
            The evidence for insulin influencing different cultured cells under high 
glucose conditions is varied and controversial. Studies on cultured mesangial 
cells treated with glucose and insulin showed insulin did not influence HSPG 
content independent of the ambient glucose levels (Olgemoller et al., 1992). 
Insulin was unable to correct the 30 mM glucose induced reduction in the 
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HSPG synthesis of rat glomerular epithelial cell layers that resemble the 
GBM (Kasinath, 1995). However, reduction in chondroitin sulfate 
proteoglycan synthesis found in articular cartilage in diabetic rats could be 
completely restored by administration of insulin (Unger et al., 1991). 
Administration of large doses of insulin restored HSPG synthesis in BM 
following reduction of HSPG by implantation of Engelbreth-Holm-Swarm 
(EHS) tumor cells in diabetic mice (Rohrbach et al., 1983). Our current 
studies showed that: insulin increased GAGs in high glucose-treated cells 
compared to insulin alone at all times and to high glucose alone at 48 and 72 
hours; insulin increased medium GAGs at all times compared to control, at 
24 and 72 hours compared to insulin alone; insulin was able to maintain high 
glucose-treated cell plus medium GAGs at control levels at 72 hours (Figure 
3.4.C). Previous studies noted that insulin alone increased ET-1 levels 
(Mandal et al., 2000). Perhaps insulin maintains HSPGs under 
hyperglycemic conditions through its effects on ET-1. Although these studies 
indicate that insulin has the potential to improve hyperglycemia-induced 
alteration of HSPG in ECs, the effect is time dependent. It is possible that 
insulin modulation of proteoglycan metabolism under hyperglycemic 
conditions is cell or tissue-specific and specific for individual species of 
proteoglycans.    
            Heparin, used as an antithrombotic drug, is also considered a potent 
vasodilator (Mandal et al., 1995), and lowers blood pressure (Yokokawa et 
al., 1994). Heparin has the ability to inhibit heparanase upregulation induced 
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by high glucose in cultured ECs (Han et al., 2007). Our results suggest that 
heparin increases GAG content in cells treated with high glucose suggesting 
the protective effect of heparin on ECs. Taken together with evidence that 
heparin stimulates HS synthesis and modification of HS in ECs (Nader et al., 
1989; Nader et al., 1991), this further suggests that heparin’s protective 
action may occur due to an increase in GAG synthesis or inhibition of 
heparanase production. 
            In summary, ECs are targets for hyperglycemia in diabetes mellitus, 
resulting in cardiovascular complications. Alteration of GAGs synthesized by 
cells is an important pathological mechanism, which can be correlated with 
cell injury by hyperglycemia. Insulin or heparin undoubtedly protects cell 
GAGs from degradation and/or increases GAG synthesis which may protect 
cells from high glucose injury. These results confirm the efficacy of insulin as 
a therapeutic drug for the diabetic patient since it not only lowers blood 
glucose levels, but also protects the vasculature. The effectiveness of 
heparin on the protection of ECs through maintaining GAG content was also 
confirmed. Elevated insulin alone without hyperglycemia may have a 
damaging effect. The exact mechanism of insulin influence on EC HSPG 
metabolism needs to be further elucidated at the levels of gene expression, 
and cell signaling pathways. 
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4. Characteristics of Heparan Sulfate Disaccharides in 
    Endothelial Cells Treated with High Glucose 
 
4.1. Abstract 
            HS is a sulfated polysaccharide that is found on the surface of most 
cells and is present in the ECM. The changes in HS disaccharide content in 
ECs under high glucose conditions are unknown. Our objectives were to 
isolate and determine total amount of GAGs in cells and medium of control 
and high glucose-treated EC cultures and to characterize HS disaccharides 
present in the recovered GAGs. Total GAGs were determined by the 
carbazole assay and HS disaccharides were determined by HPLC. The 
characterization of disaccharides recovered differ in medium but not in cells 
between control and glucose-treated cultures. Both total GAGs and HS 
disaccharides were decreased in ECs and increased in medium with high 
glucose treatment. 
4.2. Introduction 
            HSPGs are found on the surface of most cells and are part of the 
ECM. HS GAGs are part of the proteoglycans and consist of repeating units 
of disaccharides that are highly variable in structure. HS has been shown to 
bind and regulate the activities of many proteins, including enzymes, growth 
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factors, ECM proteins, and the cell surface proteins of pathogens (Bernfield 
et al., 1999; Rostand and Esko, 1997). Genetic studies have recently shown 
that HS interaction with proteins reflects its ability to regulate biological 
processes, such as cell signaling and morphogenesis in vivo (Lander and 
Selleck, 2000; Perrimon and Bernfield, 2000). Several disease conditions 
such as cardiovascular diseases, cancer, inflammation, diabetes and 
amyloidosis are associated with changes in structural and functional 
alterations of GAG components (Iozzo and Cohen, 1993; Jackson, 1997; 
Rosenberg et al., 1997; van der Woude and van Det, 1997). HS degradation 
has been found in diabetic nephropathy, skin BM and other organs. However, 
the changes in HS disaccharide content in ECs under high glucose 
conditions are unknown. The present study was to determine the effect of 
high glucose on changes in GAG content and HS disaccharide composition 
in cultured ECs and medium. Total GAGs were determined by the carbazole 
assay and HS disaccharides were determined by HPLC.  
4.3. Methods  
            Treatment of Cells: Six 60 mm dishes of porcine aortic ECs 
(Passage 4) were cultured in serum-free medium. Three dishes were used 
as control (M199) and three were treated with high glucose (30 mM) for 24, 
48 and 72 hours. 
            Collection of Samples: Medium was collected from each dish into 
15 ml centrifuge tubes. Cells were washed once with calcium magnesium 
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free-DPBS (CMF-DPBS), scraped from the dish using a cell scraper, and 
collected into 1.5 ml tubes using 1 ml CMF-DPBS. Then cell pellets were 
collected by centrifugation. All samples were stored at - 80 °C. 
            Extraction and Determination of total GAGs: Similar methods 
were used to extract and determine total GAGs as described in the methods 
in Chapter 3. 
            Obtaining HS Disaccharides: After freeze-drying, total GAGs were 
digested by chondroitinases A, B, C and ACII. Samples were passed through 
the Microcon YM-3 Centrifugal Filter Devices (Millipore, USA) to remove 
degraded chondroitin sulfates. Heparan sulfate stayed on the membrane in 
the devices. Heparinase I, II and III were added to the membrane and HS 
was digested into HS disaccharides. The detailed method is described in 
Chapter 3.2.6. 
            Analysis of HS Disaccharides: Freeze-dried digested HS, dissolved 
in 10 µl DD water was run on HPLC to determine the amount and 
characteristics of HS disaccharides. The detailed method is described in 
Chapter 3.2.6. 
4.4. Results 
    4.4.1. Total GAGs 
            When GAGs were determined by the carbazole assay, the amount of 
GAGs increased with time in both control cells and medium. Data are shown 
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in Table 4.1, the amount of GAGs is higher in cultured cells than in medium, 
both in control and high glucose-treated cultures at all times.  
4.4.2. Total HS Disaccharides  
           The total amount of HS disaccharides as determined by HPLC was 
increased both in control cells and medium when 72 hour was compared to 
24 hour. This is also correlated with that for total GAGs as shown in Table 
4.2. 
    4.4.3. Characteristics of HS Derived from PAEC Cultures 
            As shown in Figure 4.1 and 4.2, eight disaccharides were detected, 
by HPLC, in the HS standard. The eight disaccharides are: 1: ΔUA-GlcNAc, 
2: ΔUA-GlcNS, 3: ΔUA-GlcNAc6S, 4: ΔUA2S-GlcNAc, 5: ΔUA-GlcNS6S, 6: 
ΔUA2S-GlcNS, 7: ΔUA2S-GlcNAc6S, 8: ΔUA2S-GlcNS6S. Two HS 
disaccharides #4 and #5 were absent in cultured PAECs compared to 
standard as shown in Figure 4.1.B. There was no difference between control 
and high glucose-treated cells in terms of types of disaccharide, but the 
amount of disaccharides obtained from control cells was more than glucose-
treated cells shown by comparing the values on the Y-axis for control versus 
high glucose (Figure 4.1.B and C). Disaccharides #4, 6 and 8 were not 
detectable in control medium (Figure 4.2.B). There was no diference in the 
amount of disaccharides from control versus glucose medium, but an 
additional disaccharide #5 along with #4, 6 and 8 was not detectable in high 
glucose-treated medium (Figure 4.2.C).  
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Table 4.1.   Total GAGs Isolated from Cells and Medium  
 
       
            
 
 
 
 
 
 
Control cells and cells treated with high glucose (30 mM) were cultured for 24, 48, 
72 hours (1 sample/group). Then GAGs were isolated from cells and medium and 
determined by the carbazole assay. 
 
 
 
 
 
 
 
 
Sample                                Cell                      Medium
Control                   Glucose                          Control                  Glucose
Hours 24     48     72           24     48     72            24    48    72              24    48    72 
Conc. 
(µg/ml) 9.7    11.7    12.1      11.7   8.9    11.3             5.4    7.7    7.9             5.1   5.5   6.2
Total
(µg)         0.97  1.17    1.21       1.17  0.89   1.13           0.54  0.77  0.79           0.51 0.55  0.62
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Table 4.2.  Total Amount of HS Disaccharides Associated with Total GAGs in    
                  Control Cultures 
 
 
 
 
 
 
 
 
Control cells and cells treated with high glucose (30 mM) were cultured for 24, 48, 
72 hours (1 sample/group). Then GAGs were isolated from cells and medium and 
determined by the carbazole assay. HS disaccharides were determined by HPLC. 
* Total HS refers to the combination of total amount of each individual HS 
disaccharide. 
 
 
 
 
 
 
____________________________________________________________________
Sample                               Cell                       Medium   
____________________________________________________________________
Hours                 24              48              72        24              48              72
_____________________________________________________________________
Total HS*           
(ng)                145.9           39.0         383.6             53.1          30.8          119.9
_____________________________________________________________________
Total GAGs
(ug)                   0.97          1.17           1.21           0.54           0.77         0.79   
_____________________________________________________________________
*Total HS refers to total amount of HS disaccharides analysed by HPLC
These experiments were done in Dr. Linhardt Lab in USA last year, 
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Figure 4.1. HS Disaccharide Peaks Shown in HPLC Analysis for Control and 
High Glucose-treated Cells at 72 Hours 
A: Eight HS disaccharide peaks detected by HPLC in the HS disaccharide standard. 
B: HS disaccharides isolated from control cells for 72 hours. C: HS disaccharides 
isolated from high glucose-treated cells for 72 hours. 
The eight disaccharides are: 1: ΔUA-GlcNAc, 2: ΔUA-GlcNS, 3: ΔUA-GlcNAc6S, 
4: ΔUA2S-GlcNAc*, 5: ΔUA-GlcNS6S, 6: ΔUA2S-GlcNS, 7: ΔUA2S-GlcNAc6S*, 
8: ΔUA2S-GlcNS6S. 
* Disaccharides not detected in cells. 
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Figure 4.2. HS Disaccharide Peaks Shown in HPLC Analysis for Control and 
High Glucose-treated Medium at 72 Hours 
A: Eight HS disaccharide peaks detected by HPLC in the HS disaccharide standard. 
D: HS disaccharides isolated from control medium for 72 hours. E: HS disaccharides 
isolated from high glucose-treated medium for 72 hours. 
The eight disaccharides are: 1: ΔUA-GlcNAc, 2: ΔUA-GlcNS, 3: ΔUA-GlcNAc6S, 
4: ΔUA2S-GlcNAc*, 5: ΔUA-GlcNS6S**, 6: ΔUA2S-GlcNS*, 7: ΔUA2S-
GlcNAc6S, 8: ΔUA2S-GlcNS6S*. 
* Disaccharide was not detactable in control medium. 
** Additional disaccharide not detected in high glucose-treated medium. 
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    4.4.4. HS Disaccharide in Control Cells and Medium  
            Cells contained more HS disaccharides than medium as shown in 
Figure 4.3 at 24 hours and Figure 4.4 at 72 hours. At 24 hours, the 
unsaturated disaccharides UA2S-GlcNAc, UA-GlcNS6S and UA2S-
GlcNAc6S were not detected in both cells and medium. As well UA-GlcNS, 
UA2S-GlcNS and A2S-GlcNS6S were not detected in medium. At 72 hours 
UA2S-GlcNAc and UA2S-GlcNAc6S were not detected in both cells and 
medium, while only UA-GlcNS6S was not detected in medium. However, the 
combination of total individual disacharides was much higher in cells than 
medium both at 24 and 72 hours. 
    4.4.5. HS Disaccharides in Cells Treated with/without High Glucose 
            Control cells had more HS disaccharides than cells treated with high 
glucose shown in Figure 4. 5 at 24 hours and Figure 4.6 at 72 hours. The 
unsaturated disaccharides UA2S-GlcNAc, UA-GlcNS6S and UA2S-
GlcNAc6S were not detected in both control and glucose-treated cells at 24 
hours. The unsaturated disaccharides UA2S-GlcNAc and UA2S-GlcNAc6S 
were not detected in both control and glucose-treated cells at 72 hours. 
However, the combination of total individual disacharides was much higher in 
control cells than glucose-treated cells both at 24 and 72 hours. 
    4.4.6. HS Disaccharidess in Medium Treated with/without High 
Glucose 
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Figure 4.3. HS Disaccharide in Control Cells and Medium at 24 Hours 
Total GAGs were isolated from cells and medium and digested by chondroitinases 
and heparinases. Unsaturated disaccharides were determined by HPLC.  
C-C-24: control cells 24 hour treatment; M-C-24: control medium 24 hour treatment 
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Figure 4.4. HS Disaccharides in Control Cells and Medium at 72 Hours 
Total GAGs were isolated from control cells and medium and were digested by 
chondroitinases and heparinases. Unsaturated disaccharides were determined by HPLC. 
C-C-24: control cells 72 hour treatment; M-C-72: control medium 72 hour treatment 
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Figure 4.5. HS Disaccharides in Cells Treated with/without High Glucose 
                   for 24 Hours 
Total GAGs were isolated from control and high glucose-treated cells and medium and 
were digested by chondroitinases and heparinases. Unsaturated disaccharides were 
determined by HPLC.  
C-C-24: control cells 24 hour treatment; C-G-24: cells with 24 hour high glucose 
treatment. 
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Figure 4.6. HS Disaccharides in Cells Treated with/without High Glucose 
                   for 72 Hours 
Total GAGs were isolated from control and glucose-treated cells and medium and were 
digested by chondroitinases and heparinases. Unsaturated disaccharides were 
determined by HPLC.  
C-C-72: control cells 72 hour treatment; C-G-72: cells with 72 hour glucose treatment. 
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            High glucose-treated medium had more total HS disaccharides than 
control medium at 72 hours as shown in Figure 4.7. This was not consistent 
for all disaccharides. The unsaturated disaccharide UA2S-GlcNAc was not 
detected in both control and glucose-treated medium, while UA-GlcNS6S, 
UA2S-GlcNS and A2S-GlcNS6S in glucose-treated medium and UA2S-
GlcNAc6S in control medium were not detected. 
4.5. Discussion 
            These preliminary (one experiment) results showed that ECs 
contained more GAGs than medium in both control and glucose-treated 
cultures and the amount of GAGs increased with time in both cells and 
medium indicating that most of GAGs attached to the cell membrane or ECM 
are not secreted into the medium. These results are consistent with those 
described in Chapter 3.  
            Analysis of the total amount of HS disaccharides by HPLC in this 
study showed that more HS disaccharides were found in control than high 
glucose-treated ECs, while more HS disaccharides were in high glucose-
treated medium than control medium. These data further confirmed that high 
glucose not only decreased total GAGs, but actually decreased the basic 
structure unit of GAGs, the HS disaccharide. This is an area open to further 
investigation, particularly the enzymes involved in HS GAG synthesis or 
degradation under hyperglycemic conditions. The positive correlation  
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Figure 4.7. HS Disaccharides in Medium for 72 Hours Treated with/without 
High Glucose 
Total GAGs were isolated from control and high glucose-treated cells and medium 
and were digested by chondroitinases and heparinases. Unsaturated disaccharides 
were determined by HPLC.  
M-C-72: control medium 72 hour treatment; C-G-72: medium 72 hour high glucose 
treatment. 
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between total GAGs and total HS disaccharides suggested that changes in 
GAG content is due to changes in HS disaccharides.  
            Primarily, HS disaccharides extracted from both control and high 
glucose-treated ECs and control medium contained six disaccharides and 
glucose-treated medium contained five disaccharides compared to the HS 
disaccharide standard which shows eight disaccharides suggesting an effect 
of high glucose on HS disaccharide composition. These results raise the 
questions as to whether ECs from different sources or different cells from the 
same species produce all or some of the eight disaccharides for GAG 
synthesis. 
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5. Gene Alteration of Proteoglycans and Heparanase           
in Endothelial Cells under Hyperglycemic    
Conditions: The Effect of Insulin and Heparin 
5.1. Abstract 
            HSPGs are macromolecules containing a core protein with GAG 
chains attached. HSPGs in the vasculature are mainly syndecans on the cell 
membrane and perlecan in the ECM which are synthesized by ECs. 
Reduced HSPG is associated with EC dysfunction in hyperglycemia which is 
a risk factor for diabetic cardiovascular complications. Changes in HSPG 
core protein and mRNA in diabetes remain controversial. Although 
heparanase is believed to break down HS, its effect on core protein is 
unknown. The present study was to determine if mRNA of core proteins of 
syndecan and perlecan from cultured ECs were altered by high glucose and 
if this was correlated with heparanase mRNA expression. As well, the effect 
of heparin and insulin on expression of these three genes was studied. 
Confluent human aortic endothelial cells (HAECs) were treated with high 
glucose (30 mM) and/or insulin (0.01 unit/ml) and/or heparin (0.5 µg/ml) for 
24 hours. Total RNA was isolated from cells and cDNA was synthesized. 
Then Real time PCR analysis revealed that high glucose increased 
heparanase, decreased syndecan and had no effect on perlecan gene 
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expression. Heparin alone decreased heparanase and perlecan mRNA, and 
increased syndecan mRNA. Insulin alone decreased mRNA expression of 
heparanase and perlecan, but had no effect on syndecan. When high 
glucose was present, heparin decreased mRNA expression of heparanase 
and perlecan and increased that of syndecan compared to high glucose 
treatment. Insulin in the presence of high glucose decreased expression of 
perlecan compared to control, of syndecan compared to control and heparin 
alone, and of heparanase compared to glucose alone. Heparin and insulin in 
combination decreased perlecan mRNA compared to control and glucose 
treatment and increased mRNAs of syndecan and heparanase compared to 
all other treatments. We conclude that heparin may protect cells from high 
glucose injury by enhancing syndecan and inhibiting heparanase production. 
Insulin alone decreased heparanase and perlecan mRNA in the presence 
and absence of high glucose and syndecan in the presence of high glucose 
suggesting that insulin may protect cells by inhibiting heparanase mRNA and 
may be harmful to cells by decreasing perlecan and syndecan mRNA. The 
combination of insulin and heparin protects cells from high glucose injury by 
increasing syndecan, but does not decrease heparanase mRNA, suggesting 
a possible interference of insulin and heparin in gene regulation at the 
transcriptional levels for heparanase mRNA expression.  
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5.2. Introduction 
            Hyperglycemia is an independent risk factor for cardiovascular 
complications in diabetes mellitus. One of the potential mechanisms of 
diabetic cardiovascular complications caused by hyperglycemia is the 
impaired function of ECs. Endothelial cells play a crucial role in the regulation 
of vascular tone and permeability and in the maintenance of homeostasis. A 
number of mechanisms have been suggested to mediate endothelial 
dysfunction in hyperglycemia that may be related to the pathogenesis of 
diabetic endothelial damage. These include increased tissue oxidative stress, 
increased production of AGEs, altered coagulation and fibrinolytic processes, 
and increased production of cytokines (Elliott et al., 1993). In addition, 
degradation of HSPGs could be an important mechanism for endothelial 
dysfunction due to release of bioactive factors associated with HS chains 
(Kanwar et al., 1980).  
            HSPGs are macromolecules found in all mammalian tissues and 
cells.  HSPGs normally consist of two to three HS chains positioned in close 
proximity to each other along protein cores that localize proteoglycans to the 
cell surface or to ECM (Gallagher et al., 1986). HS is a prominent component 
of blood vessels and the most common GAG found on the EC surface and in 
the ECM.  Typical HSPGs in the vasculature are syndecans and perlecan. 
Both can be synthesized and secreted by ECs under normal physiological 
conditions. Syndecans are mainly expressed on the cell surface and 
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perlecan is presented in the ECM and BM (Kaji et al., 2000). It has been 
shown that the biosynthesis of HSPG and HS chain sulfation is decreased in 
the hyperglycaemic state (Jensen, 1997; Kjellen et al., 1983). HS GAGs were 
decreased in arteries of diabetic patients (Wasty et al., 1993). HS GAGs but 
not core protein were decreased in cultured ECs and kidney cells treated 
with high glucose (van Det et al., 1996b; Vogl-Willis and Edwards, 2004b). 
Immunofluorescence studies of renal biopsies also showed a decrease in 
staining of HS GAGs without changes in core protein staining (Tamsma et 
al., 1994). The concentration of arterial HS was negatively correlated with 
plasma glucose concentration in diabetic monkeys (Edwards et al., 2004). 
However, it is unknown whether the decrease in GAGs is accompanied by, 
or independent of, a decrease in the gene expression of core protein under 
hyperglycemic conditions in vascular ECs.  
            Heparanase induced by high glucose in ECs could be responsible for 
the cleavage of HS chains but not core proteins of HSPGs, since heparanase 
is an endoglucuronidase and breaks down HS chains but not proteins. 
Heparanase mRNA and protein activity were expressed in ECs treated with 
high glucose (Han et al., 2007). Studies in brain melanoma cells have shown 
that cell surface syndecan (syndecan-1) and ECM perlecan were targets for 
heparanase degradation (Reiland et al., 2004). However, the correlation 
between decreased HSPGs such as syndecan and perlecan and increased 
heparanase in ECs under hyperglycemic conditons has not been studied. 
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            In addition to its antithrombotic activities, heparin is considered a 
potent vasodilator (Mandal et al., 1995) and lowers blood pressure in 
spontaneously hypertensive rats (Yokokawa et al., 1994). Heparin has the 
ability to inhibit heparanase upregulation induced by high glucose in cultured 
ECs (Han et al., 2007). Insulin can also inhibit heparanase expression in ECs 
treated with high glucose (Han et al., 2007). Although both heparin and 
insulin affect the expression of heparanase in ECs treated with high glucose, 
the influence of these two compounds on the core proteins of the HSPGs 
syndecan and perlecan in ECs under hyperglycaemic conditions is still a 
mystery. In the present study, cultured HAECs treated with high glucose and 
heparin and/or insulin were used as an in vitro model. Gene expression of 
syndecan, perlecan and heparanase were determined by real time 
quantitative PCR to determine if high glucose and insulin or heparin influence 
expression of these genes. The mechanism of gene regulation at the 
transcriptional level was also studied.  
5.3. Materials and Methods 
    5.3.1. Human Aortic Endothelial Cell (HAEC) Cultures 
            HAECs and their basal medium (Medium 200) and cell growth 
supplement (LSGS kit) were purchased from Cascade Biologics (Portland, 
OR, USA). HAECs were transferred into 30 ml flasks from a vial of frozen 
cells and were cultured at 37°C with 5% CO2/95% air in a humidified 
environment until confluent. Then confluent HAECs in flasks were washed 
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twice with magnesium-free Dulbecco's phosphate-buffered saline (CMF-
DPBS) and cells were detached by trypsin (0.025% with EDTA in CMF-
DPBS) for two or three minutes at room temperature. The cells were 
resuspended in medium and transferred to 35 mm dishes for further 
experiments. 
    5.3.2. Treatment of Cultures 
            When HAECs were grown to confluence, they were incubated with 
seven different treatments (3 dishes/group) including control, glucose (30 
mM), insulin (0.01 unit/ml), heparin (0.5 µg/ml), glucose plus insulin, glucose 
plus heparin and glucose plus insulin plus heparin for 24 hours. In a separate 
study, confluent HAECs cultured in 35 mm dishes were divided into five 
different groups (3 dishes/group) and were treated with glucose (30 mM), 
glucose plus actinomycin D (10 µg/ml), glucose plus insulin plus heparin and 
glucose plus insulin plus heparin plus actinomycin D for 2, 4, 8 and 24 hours. 
A control group was treated with medium.  
    5.3.3. Extraction of Total RNA 
            RNeasy® Mini Kit from QIAGEN (Mississauga, Ontario, CA) was used 
to isolate total RNAs from HAECs. Briefly, media were removed from dishes, 
and then cells were washed with cold CMF-DPBS (4°C). Procedural steps 
from the lysis of cells to obtaining total RNAs were performed according to 
the manufacturer’s instructions. The concentrations of RNAs were 
determined by a NanodropTM 1000 Spectrophotometer (Thermo Scientific). A 
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ratio of absorbance at 260/280 nm >/= 2.0 indicated RNA pure enough to use 
for cDNA synthesis. 
    5.3.4. Synthesis of cDNA 
            The AffinityScriptTM QPCR cDNA Synthesis Kit from Stratagene (La 
Jolla, CA, USA) was used to create cDNA from RNAs of cells with all 
treatments. A total of 1 µg RNA from each sample was used for cDNA 
synthesis in a 20 µl reaction according to the methods described in the 
manufacturer’s instruction. The Oligo (dT) primer (3 µl each reaction) was 
used. The reaction program was: the primer annealing at 25°C for 5 minutes, 
cDNA synthesis at 45°C for 15 minutes and the termination of the reaction at 
95°C for 5 minutes. The newly synthesized cDNAs were stored at -20°C for 
later use.  
    5.3.5. Detection of Gene Expression by Real Time  
              Quantitative PCR 
            Brilliant® II SYBR® Green QPCR Master Mix Kit (Stratagene) was 
used for determination of gene expression from samples of synthesized 
cDNA. The cDNA samples were diluted 20 times prior to the set up of the 
PCR reactions. The primers were used as following: heparanase sense 
primer 5’-GGCAAGTATTCTTTGGAGCA-3’ and antisense primer 5’-TGGAT 
TGTCAGTGTTTGTGC-3’; perlecan sense primer 5’-TGCCTGAGGACATAG 
AGACC-3’ and antisense primer 5’-TCGGAATAAACCATCTGGA-3’; 
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syndecan-1 sense primer 5’-TGCAGGTGCTTTGCAAGATA-3’ and antisense 
primer 5’-TTCTGGAGACGTGGGAATA-3’; β-actin (internal control) sense 
primer 5’-GGCATCCTCACCCTGAAGTA-3’ and antisense primer 5’-
GAAGGTCTCAAACATGATCT-3’. In a 25 µl reagent mixture, assembled 
according to the manufacture’s instructions, final concentrations for each 
primer was 200 nM alone with 5 µl for each template cDNA. The real time 
PCR reactions were performed in Mx3005P® QPCR Systems from 
Stratagene. The PCR cycling programs used were: 1 cycle at 95°C for 10 
minutes to activate the DNA polymerase and 40 cycles at 95°C for 30 
seconds, 58°C for 1 minute and 72°C for 1 minute to detect and report 
fluorescence during the annealing and extension step of each cycle.  
    5.3.6. Statistic Analysis 
            Relative gene expression data were calculated by using the CT value 
of real time quantitative PCR following the 2-ΔΔCT method decribed by Livak et 
al., (Livak and Schmittgen, 2001). The formula was ΔΔCT = (CT - 
CTActin)Treatment - (CT - CTActin)Control. Using the 2
-ΔΔCT method the data are 
presented as the fold change in gene expression normalized to the 
housekeeping reference gene β-actin and relative to the untreated control. 
For the untreated control sample, ΔΔCT equals zero and 2
0 equals one, so 
that the fold change in gene expression is relative to the untreated control 
which equals one. For the treated samples, evaluation of 2-ΔΔCT indicates the 
fold change in gene expression relative to the untreated control. For the 
regulation of gene expression by actinomycin D, relative gene changes at 
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different times compared to time 0 was also calculated by using the 2-ΔCT 
method, where ΔCT= CT.time 0 - CT.time n.  
            All data is expressed as mean +/- standard deviation (SD) from three 
culture dishes per group. A one-way ANOVA was used to determine 
significant differences between groups with p<0.05 considered significant. A 
two-tailed t-test was used to test difference between two groups with p<0.05 
considered significant. The regression analysis shows relative mRNA 
inhibited by actinomycin D with time. 
5.4. Results 
    5.4.1. Gene Expression 
            To determine the correlation of expression of the genes perlecan, 
syndecan and heparanase under hyperglycemic conditions and the effect of 
insulin and/or heparin, total RNAs were isolated from seven groups of 
cultured cells with different treatments including control, high glucose, 
heparin, insulin, high glucose plus insulin, high glucose plus heparin, and 
high glucose plus insulin plus heparin. Then, cDNAs were synthesized from 
RNAs and gene expression was detected by quantitative real time PCR. The 
right products of real time PCR for heparanase, syndecana and perlecan 
were confirmed by gel electrophoresis and dissociation curve as shown in 
Figure 5.1. 
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A: 
 
B: 
 
 
 
 
 
Figure 5.1. Confirmation of Real Time PCR Products 
Control endothelial cells and cells treated with high glucose for 24 hours. Total 
RNAs were isolated from cells. cDNAs were synthesized. Real time quantitative 
PCR was performed with cDNA to amplify heparanase, syndecan and perlecan 
mRNAs. A:  Gel electrophoresis shown:  Lane 1: 100bp DNA ladder; Lane 2 
(control) and Lane 3 (glucose) for Heparanase mRNA; Lane 4 (control) and Lane 5 
(glucose) for Perlecan; Lane 6 (control) and Lane 7 (glucose) for Syndecan; Lane 8 
(control) and Lane 9 (glucose) for β-actin; Lane 10: no template control. B: 
Dissociation curve for heparanase, perlecan, syndecan and β-actin. 
1               2              3              4             5   6             7              8             9           10
200bp
Heparanase
Syndecan Actin
Perlecan
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            Heparanase mRNA Expression:  As shown in Figure 5.2., 
heparanase mRNA was expressed in control cultured ECs. High glucose 
significantly increased heparanase mRNA expression compared to control. 
Heparin or insulin alone had no effect on heparanase mRNA expression. In 
the presence of high glucose, insulin or heparin alone decreased heparanase 
mRNA expression compared to high glucose alone, while the combination of 
insulin and heparin enhanced heparanase mRNA expression even further 
than high glucose alone. 
            Syndecan mRNA Expression:  As shown in Figure 5.3., syndecan 
mRNA was normally expressed in control cultured ECs. High glucose alone 
inhibited syndecan mRNA expression. Insulin or heparin alone did not have 
any effect on syndecan mRNA expression. When high glucose was present, 
heparin, but not insulin, restored syndecan mRNA to control levels. Insulin 
plus heparin increased syndecan mRNA expression significantly compared 
to all other groups. 
            Perlecan mRNA Expression:  As shown in Figure 5.4., perlecan 
mRNA was normally expressed in control cultured ECs. Glucose alone did 
not significantly affect perlecan mRNA expression. Insulin or heparin alone 
significantly decreased perlecan mRNA expression compared to control. 
When high glucose was present, insulin, heparin and insulin plus heparin 
significantly decreased perlecan mRNA expression. Also when high glucose 
was present, heparin and insulin plus heparin significantly decreased 
perlecan mRNA expression compared to glucose alone. 
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Figure 5.2. Heparanase mRNA Expression in Endothelial Cells Treated with 
High Glucose and/or Insulin and/or Heparin 
 
Endothelial cells were treated with high glucose (Glu) and/or insulin (Ins) and/or 
heparin (Hep) for 24 hours. Total RNAs were isolated from cells. cDNAs were 
synthesized. Real time quantitative PCR was performed with cDNA to amplify 
heparanase mRNA. 
 a, significantly different from all other groups; b, significantly different from 
glucose treatment, p<0.05, one-way ANOVA.  
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Figure 5.3. Syndecan mRNA Expression in Endothelial Cells Treated with High 
Glucose and/or Insulin and/or Heparin 
 
Endothelial cells were treated with high glucose (Glu) and/or insulin (Ins) and/or 
heparin (Hep) for 24 hours. Total RNAs were isolated from cells. cDNAs were 
synthesized. Real time quantitative PCR were performed with cDNAs to amplify the 
syndecan mRNA.  
a, significantly different from control (Ctrl); b, significantly different from glucose 
(Glu)  treatment; c, significantly different from heparin (Hep); e, significantly 
different from all other groups, p<0.05,  one-way ANOVA. 
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Figure 5.4.  Perlecan mRNA Expression in Endothelial Cells Treated with High 
Glucose and/or Insulin and/or Heparin 
 
Endothelial cells were treated with high glucose (Glu) and/or insulin (Ins) and/or 
heparin (Hep) for 24 hours. Total RNAs were isolated from cells. cDNAs were 
synthesized. Real time quantitative PCR were performed with cDNAs to amplify the 
perlecan mRNA. 
a, Significantly different from control (Ctrl); b, significantly different from glucose 
(Glu) treatment, p<0.05, one-way ANOVA. 
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    5.4.2. Mechanism of Gene Regulation 
            To determine the mechanism of gene expression, the samples with 
highest levels of mRNAs from real time PCR detection, the heparanase 
mRNA treated with high glucose or high glucose plus insulin plus heparin 
and syndecan mRNA treated with high glucose plus insulin plus heparin, 
were treated with (+) or without (-) addition of actinomycin D. 
            The results from the effect of actinomycin D on heparanase mRNA 
expression induced by high glucose are shown in Figure 5.5.A. Heparanase 
mRNA expression relative to the housekeeping gene β-actin was increased 
with time in high glucose-treated cells with or without actinomycin D and was 
significantly increased at 24 hours compared to 0 hours. The expression of 
heparanase mRNA was increased and β-actin mRNA did not change in cells 
not treated with actinomycin D (Figure 5.5.B), while the expression of β-actin 
steadily decreased with time, and heparanase increased and then decreased 
to slightly below control levels at 24 hours in cells treated with actinomycin D 
(Figure 5.5.C).              
            In cells treated with high glucose plus insulin plus heparin, 
heparanase mRNA expression was significantly increased in cells without 
actinomycin D at 24 hours compared to 0 hours but not in cells with 
actinomycin D as shown in Figure 5.6.A. At 24 hours, heparanase mRNA in 
cells without actinomycin D was significantly different from cells with 
actinomycin D, when compared 2, 4, 8, and 24 hour to their own expression  
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Figure 5.5. Effect of Actinomycin D on Heparanase mRNA Expression Induced 
by High Glucose  
Two groups of ECs were treated with high glucose and high glucose+actinomycin D 
for 0, 2, 4, 8 and 24 hours. Total RNAs were isolated and cDNAs were synthesized. 
Real time quantitative PCR was used to amplify heparanase gene. A: Relative 
heparanase mRNA expression to β-actin; B: Heparanase and β-actin mRNA at 2, 4, 
8, and 24 hours relative to time 0 -actinomycin; C: Heparanase and β-actin mRNA at 
2, 4, 8, and 24 hours relative to time 0 +actinomycin. *Significantly different from 0 
hours, p<0.05, two-tailed t-test. 
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at time 0. The expression of heparanase mRNA was increased and β-actin 
mRNA did not change in cells without actinomycin D treatment (Figure 
5.6.B), while the expression of both heparanase and β-actin was decreased 
(β-actin declined faster than heparanase) with the time in cells treated with 
actinomycin D (Figure 5.6.C). 
            The results from the effect of actinomycin D on syndecan mRNA 
expression induced by high glucose plus insulin plus heparin are shown in 
Figure 5.7.A. Syndecan mRNA expression was increased significantly in 
cells without actinomycin D, but not in cells with actinomycin D when 24 
hours is compared to 0 hours. At 24 hours syndecan mRNA expression was 
significantly greater in cells without actinomycin D than in cells with 
actinomycin D.  When comparing expression at 2, 4, 8, and 24 hours relative 
to time 0, the expression of syndecan mRNA increased and β-actin mRNA 
did not change in cells without actinomycin D (Figure 5.7.B), while the 
expression of syndecan and β-actin both decreased with the time in cells 
with actinomycin D (Figure 5.7.C). 
5.5. Discussion  
            HSPGs derived from ECs are important components in the 
vasculature. Alteration of HSPGs is a cause of endothelial dysfunction or 
injury which is involved in vascular complications. HSPG metabolism in 
general can be affected at different levels including core protein synthesis 
and GAG chain addition, elongation, sulfation and degradation. Core protein  
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Figure 5.6.  Effect of Actinomycin D on Heparanase mRNA Expression Induced 
by Glucose plus Insulin plus Heparin 
Two groups of ECs were treated with high glucose and high glucose+actinomycin D 
for 2, 4, 8 and 24 hours. Total RNAs were isolated and cDNAs were synthesized. 
Real time quantitative PCR was used to amplify the heparanase gene. A: Relative 
heparanase mRNA expression to β-actin; B: Heparanase and β-actin mRNA at 2, 4, 
8, and 24 hours relative to time 0 -actinomycin; C: Heparanase and β-actin mRNA at 
2, 4, 8, and 24 hours relative to time 0 of +actinomycin. *Significantly different 
from 0 hour, 
Ұ 
significantly different between actinomycin D addition and non-
addition, p<0.05, two-tailed t-test. 
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Figure 5.7. Effect of Actinomycin D on Syndecan mRNA Expression Induced by 
Glucose plus Insulin plus Heparin 
Two groups of ECs were treated with glucose+insulin+heparin +/-actinomycin D for 
2, 4, 8 and 24 hours. Total RNAs were isolated and cDNAs were synthesized. Real 
time quantitative PCR was used to amplify syndecan gene. A: Relative syndecan 
mRNA expression to β-actin; B: Syndecan and β-actin mRNA at 2, 4, 8, and 24 
hours relative to time 0 -actinomycin; C: Syndecan and β-actin mRNA at 2, 4, 8, and 
24 hours relative to time 0+actinomycin. *Significantly different from 0 hours,Ұ 
significantly different between actinomycin D addition and non-addition. p<0.05, 
two-tailed t-test. 
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synthesis is controlled by transcription of DNA to mRNA and translation of 
mRNA to protein. Changes in HSPG synthesis and turnover will affect the 
endothelium to a large extent. There is accumulating evidence in diabetic 
patients, animal models, and in cultured cells from different sources under 
hyperglycemic conditions to suggest that decreased HSPG is an important 
factor contributing to diabetic cardiovascular complications. HS chains are 
believed to be degraded by heparanase, an endo-β-D-glucuronidase capable 
of cleaving glycosidic bonds of HS side chains at a limited number of sites 
with a hydrolase mechanism (Vlodavsky and Friedmann, 2001). Induction of 
heparanase by high glucose is at least partly responsible for HS degradation 
in diabetes, however, it is still unknown if core proteins of syndecan on the 
cell surface or perlecan in the ECM are also affected by high glucose or 
correlated with heparanase induction in ECs under hyperglycemic conditions.  
            In the present study, the effect of high glucose on gene expression 
and regulation of heparanase, syndecan and perlecan in HAECs was 
determined by real time quantitative PCR. We found that high glucose 
increased heparanase, decreased syndecan and had no effect on perlecan 
mRNA expression compared to control.          
            Upregulation of heparanase under hyperglycaemic conditions has 
been shown in diabetic animal models and human patients as well as in 
cultured cells from various sources. Previous studies localized heparanase 
protein both in glomeruli capillaries and tubular epithelium and detected 
heparanase activity in the urine of diabetic patients (Katz et al., 2002; Shafat 
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et al., 2006).  The reduction of HS in the glomeruli of patients with overt 
diabetic nephropathy in type 2 diabetes was correlated with an upregulation 
of heparanase (van den Hoven et al., 2006). Heparanase protein expression 
was inversely correlated with HS expression in mouse renal cortex with STZ-
induced diabetes (van den Hoven et al., 2006). Upregulated heparanase 
mRNA by high glucose in HAEC is consistent with our previous results where 
heparanase mRNA was upregulated by high glucose in PAECs (Han et al., 
2007) suggesting that there is no species specificity in terms of heparanase 
upregulation by high glucose in ECs. This result also confirmed that ECs are 
an important cell type that expresses and releases heparanase in patients 
with overt diabetic nephropathy (Levidiotis et al., 2001; 2004). HS chains on 
syndecan or perlecan in melanoma cells were the targets of heparanase 
degradation, and syndecan core protein was not changed by heparanase 
(Reiland et al., 2004). Heparanase inhibitors, PI-88 and heparin, reversed the 
degradation of cell surface HSPG by heparanase upregulation under 
hyperglycaemic conditions in rat and human glomerular epithelial cells as 
well as human tubular epithelial cells (Maxhimer et al., 2005). Therefore, HS 
reduction is at least partly due to accelerated degradation by increased 
heparanase expression invoked by the hyperglycaemic environment. This 
also confirmed our previous study that total GAGs were decreased in cells 
and increased in medium by high glucose (Chapter 3 of this thesis). 
            Expression of both heparanase gene and protein was detected in 
human tumor cell lines, head and neck tumors and metastic pancreatic 
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cancer, suggesting the possibility of transcriptional and translational 
regulation of heparanase (Koliopanos et al., 2001; Simizu et al., 2003; 
Vlodavsky et al., 2002). Previous studies have demonstrated that high 
glucose is able to activate several transcription factors that are involved in 
regulation of the heparanase promoter, including Sp1, early growth 
response-1 (Egr-1) and the ETS family transcription factors (Jiang et al., 
2002). A study in renal epithelial cells showed that concerted activation of 
these transcription factors by high glucose leads to the activation of 
heparanase promoter and induction of heparanase gene expression 
(Maxhimer et al., 2005). Transcription factors of the Sp1 and ETS families 
play a role in controlling the basal activity of human heparanase gene 
expression (Jiang et al., 2002; Lu et al., 2003). Egr-1 is a key activator of 
heparanase gene expression and binds to a specific element in the 
heparanase promoter regulating inducible transcription. Inducible expression 
of heparanase mRNA and the activity of heparanase promoter element are 
dependent on the ERK1/2 (MEK1/2) pathway. This pathway is critical for 
induction of Egr-1 expression at both the mRNA and protein level in T cells 
(Jiang et al., 2002; Lu et al., 2003). Our study showed that actinomycin D 
inhibited both β-actin and heparanase mRNA expression under high glucose 
conditions (Figure 5.4) suggesting transcriptional regulation of high glucose 
on heparanase gene expression occurs in ECs. Additionally, all the 
aforementioned transcriptional factors may be involved in the process of 
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heparanase gene regulation, but the action of each factor on the regulation of 
heparanase gene in ECs needs further investigation.  
            Syndecan is lost from the cell surface under a number of 
physiological conditions, and degradation of HS can result in changes in 
syndecan distribution (Sanderson, 2001; Yang et al., 2003). High glucose 
decreased the expression of syndecan mRNA, shown in this study (Figure 
5.2) suggesting that some factors induced by high glucose interfered with 
syndecan gene transcription. Syndecan expression can be regulated at both 
transcriptional and translational levels (Hayashida et al., 2006). The 
syndecan promoter has multiple proximal Sp1 binding sites (Larrain et al., 
1997) and Sp1-like transcription factors have a critical role in regulation of 
the transcriptional activity of the syndecan gene (Vihinen et al., 1996). Sp1 is 
ubiquitously expressed, and its activation and recruitment of distinct 
transduction pathways and signaling molecules may serve as mechanisms to 
promote transactivation of selected responsive genes. Regulation of Sp1-
dependent transcription may be conveyed by changes in DNA binding 
activity, by association with other transcription factors, and by changes in 
Sp1 abundance or in transactivation due to biochemical modification, such as 
phosphorylation (Black et al., 2001; Philipsen and Suske, 1999). Sp1 is 
phosphorylated by a number of cellular kinases, including DNA-dependent 
protein kinase, protein kinase A (PKA) and different members of the PKC 
family (Black et al., 2001). In a study on the terminal differentiation of liver, an 
increase in Sp1 phosphorylation decreased its DNA binding activity (Leggett 
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et al., 1995). Decrease in Sp1 activity may cause down-regulation of 
syndecan expression in ECs under hyperglycaemic conditions, since glucose 
can activate and upregulate PKC through formation of DAG and AGEs 
(Scivittaro et al., 2000). PKC is a ubiquitous family of serine-threonine 
phosphorylating enzymes (Koya and King, 1998). The distribution of over 10 
isoforms varies among cell types with PKCα and β most prevalent in the 
vasculature (Trial Research Group, 1993) where hyperglycemia 
predominately activates PKCβ (Inoguchi et al., 1992). The effects of PKC 
activation are variable including alterations in cell signalling, production of 
vasoconstrictor substances, and conversion of VSMCs and ECs to a 
proliferative phenotype in the retinal microcirculation and conduit vessels.   
Sp1 phosphorylation by PKC on the syndecan gene may decrease its 
transcription under hyperglycaemic conditions.  In addition, an increase in 
serum syndecan was shown in early nephropathy in a type 1 diabetic patient 
(Svennevig et al., 2006). Heparanase was shown responsible for syndecan 
shedding in myeloma and breast cancer cells (Yang et al., 2007) which may 
lead to increased serum syndecan in the diabetic patient. Therefore, 
heparanase induction may play a role in decreased syndecan and HS in 
vessels. There is no evidence to show the effect of heparanase on gene 
expression of syndecan. However, the present study showed that high 
glucose increased heparanase and decreased syndecan gene expression 
which may suggest the effect of heparanase on syndecan gene expression. 
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            The expression of perlecan mRNA was not changed by high glucose 
even though there was a trend to a decrease compared to control (Figure 
5.3). Changes in perlecan mRNA and protein under hyperglycemia is 
controversial in different diabetic models. A study of HS in mesangial and 
epithelial cells cultured in high glucose medium showed no changes in HSPG 
made up of mainly perlecan core protein (van Det et al., 1996b). A decrease 
in the synthesis and mRNA levels of perlecan was demonstrated in retinas 
from STZ-diabetic rats (Bollineni et al., 1997). A significant decrease in 
perlecan core protein expression and somewhat moderate reductions in its 
mRNA expression under high glucose conditions was also reported (Ha et al., 
2004). A study of bovine myocardial ECs exposed to high glucose showed 
increased sulfate incorporation into the proteoglycan with no changes in core 
protein synthesis (Klein et al., 1995). The perlecan mRNA was reduced in 
glomerular epithelial cells exposed to medium containing 30 mM glucose 
which resulted in reduction in synthesis of BM HSPG at 24 hour and 7 days 
(Kasinath et al., 1996). There were no absolute changes in kidney cortex 
levels of perlecan mRNA observed in a mouse model of type 2 diabetes 
(Raats et al., 2000). The differences in perlecan mRNA expression between 
studies may also be related to the cell type or source, exposure time to 
glucose, and culture conditions in general. Regulation of perlecan gene 
expression under hyperglycaemic conditions is beginning to be understood. 
The promoter of human perlecan has been partially sequenced, revealing 
potential binding sites for several transcription factors, including Sp1, AP-2 
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and ETF (Cohen et al., 1993). cAMP, a regulator of a wide variety of genes, 
caused a less reduction in perlecan mRNA than perlecan core protein in 
glomerular epithelial cells, indicating that both transcriptional and 
posttranscriptional mechanisms may be involved and that cAMP regulates 
posttranscriptional events in proteoglycan synthesis (Ko et al., 1996). Since 
regulation of perlecan gene expression by high glucose may be at 
transcriptional levels, the core protein or HS chains may be altered despite 
our observations of no significant change in perlecan mRNA.  
            Exogenous heparin is capable of ameliorating increased vascular 
permeability caused by various polycationic substances (Fairman et al., 
1987; Peterson et al., 1987). Heparin also has antiviral activity, binds to a 
variety of growth factors, inhibits complement activation and regulates 
angiogenesis (Casu, 1985; Lane and Lindahl, 1989). Low molecular weight 
heparin (LMWH) may prolong the survival in patients with advanced cancer 
(Kakkar et al., 2004). Therefore, heparin can protect or prevent diseases of 
the cardiovascular system and cancer processes by variety of mechanisms, 
but the exact mechanism of heparin’s therapeutic function is still not clear, 
especially in hyperglycemia induced cardiovascular complications. Therefore, 
the effect of heparin on the gene expression of syndecan, perlecan and 
heparanase may reveal a possible mechanism of therapeutic action. Heparin 
alone decreased heparanase and perlecan, and increased syndecan mRNA 
expression in this study, indicating that heparin is capable of inhibiting 
heparanase expression and enhancing the synthesis of syndecan, but not 
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perlecan. Previous studies have shown that heparin increased HS synthesis 
and prevented heparanase upregulation in ECs, and inhibited HSPG 
degradation by heparanase induction (Bar-Ner et al., 1987; Han et al., 2007; 
Nader et al., 1991). These results indicated that, at least in part, heparin may 
protect endothelium and the vasculature by increasing syndecan synthesis 
and preventing heparanase induction. However, there is no direct information 
about the regulatory mechanisms of heparin on the gene expression of 
heparanase, syndecan or perlecan in ECs. It has been shown that heparin or 
HS suppressed proliferation of mesangial and vascular smooth muscle cells 
partly by interfering with PKC signalling (Castellot, Jr. et al., 1982; Pukac et 
al., 1992). Heparin inhibits apoptosis of mesangial cells via intervention in the 
AP-1 pathway (Ishikawa et al., 1997) and the activity of AP-1 is regulated by 
both production of AP-1 protein and its activation via c-Jun N-terminal kinase 
(JNK). The inhibitory effect of heparin on the AP-1 pathway may be mainly 
through reduction in the mRNA and protein levels of AP-1 components 
(Ishikawa and Kitamura, 1999). Since mesangial cells are the main cell type 
in kidney to produce HSPG and show pathogenic changes in diabetic 
nephropathy, heparin may also influence the factors or pathways involved in 
regulation of HSPG or heparanase induction. LMWH prevented the binding 
of nuclear proteins to the regulatory AP-1 site but not to a Sp1 site in a study 
of heparin inhibiting expression of prosclerotic TGF-β1 which has been 
implicated in the pathogenesis of diabetic nephropathy (Weigert et al., 2001). 
The regulation of gene expression by heparin through AP-1 is different from 
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that of high glucose, through activating Sp1 transcription factor, suggesting 
that the possible mechanism by which heparin protects cells from high 
glucose injury is to activate AP-1 and inhibit Sp1. 
            Insulin regulates the blood glucose concentration and the metabolism 
of fats and proteins in cells. Binding of insulin to its receptors results in 
diverse signalling processes that mediate many of insulin’s actions in 
vascular cells including modulating transcription, altering cell content of 
numerous mRNAs and stimulating cell growth, DNA synthesis, and 
replication (Bornfeldt et al., 1992; Sowers, 1997). In this study, insulin 
decreased heparanase and perlecan mRNA, but had no effect on syndecan. 
Insulin upregulated PAI-1 by activiting Sp1 transcription factor binding to the 
PAI-1 promoter (Banfi et al., 2001). Rat apolipoprotein (Apo) AI gene 
expression is induced by insulin activating a promoter with a Sp1 binding site 
(Murao et al., 1998). The genes of heparanase, perlecan and syndecan 
express Sp1 binding sites on their promoter regions, therefore decreased 
mRNA expression of heparanase and perlecan may be due to Sp1 regulation 
by insulin. Activation of Sp1 may play a negative transcriptional role at 
promoter regions of heparanase and perlecan, since over-expression of Sp1 
in rat hepatocytes leads to a decrease in fat acid synthase (FAS)-promoter 
activity (Fukada et al., 1997). Syndecan mRNA expression wasn’t affected by 
insulin in the present study. However, previous evidence has shown that 
insulin promoted shedding of syndecan ectodomains from 3T3-L1 adipocytes 
(Reizes et al., 2006) and may reduce the amount and bioactivity of syndecan 
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acting on EC surface. The similar sequences between human insulin 
receptor and mouse syndecan (Ebina et al., 1985) may lead insulin to affect 
the pathways involved in syndecan biosynthesis or turn over.  Therefore, 
insulin may play a role in posttranscriptional regulation of syndecan 
expression and reduce syndecan on the cell surface although syndecan 
mRNA wasn’t effected by insulin in this study. 
            When high glucose was present, heparin decreased mRNA 
expression of  heparanase and perlecan and increased that of syndecan 
compared to high glucose treatment while insulin decreased expression of 
perlecan compared to control, syndecan compared to control and heparin 
alone, and heparanase compared to glucose alone and heparin plus insulin 
with high glucose treatment. Heparin and insulin in combination decreased 
perlecan mRNA compared to control and glucose treatment and increased 
mRNAs of syndecan and heparanase compared to all other treatments. 
These results suggest that the influence of heparin and/or insulin on 
expression of these three genes is complicated in the presence of high 
glucose. As mentioned previously in the discussion, heparin or insulin 
regulate gene expression by interacting with different transcriptional factors 
although these transcriptional binding sites are present on all these genes. 
The action of the same transcriptional factor on different genes may show 
positive or negative regulation. Additionally, the glucose response element 
(GRE) has been identified in the promoters of a variety of glucose regulated 
genes and involved in upregulation of the gene expression (Shih and Towle, 
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1992; Thompson and Towle, 1991; Vaulont and Kahn, 1994). It is possible 
there are alternative sites regulated by heparin, insulin or glucose in the 
promoter regions of heparanase, syndecan, and perlecan genes. As shown 
in actinomycin D treated cells under the treatment of high glucose plus 
insulin and heparin (Figure 5.5 and 5.6), both syndecan and heparanase 
genes are regulated at the transcriptional level. However, transcriptional 
regulation of heparanase in cells treated with high glucose alone was not 
shown when relative heparanase mRNA was compared to the housekeeping 
gene β-actin. However, transcriptional regulation was confirmed by 
comparing relative heparanase mRNA to its own expression at time 0.  
These results indicate that the expression of heparanase gene was 
alternatively regulated by high glucose or by high glucose plus insulin plus 
heparin. Further investigation is needed to identify intermediary steps and 
effectors involved in genetic regulation of HSPG core proteins by high 
glucose.  
            We observed in this study that heparin decreased heparanase and 
increased syndecan mRNA expression in high glucose-treated cells 
indicating the protective effect on ECs. Perlecan mRNA in cells treated with 
high glucose was decreased by heparin and/or insulin and suggests that 
regulation of ECM perlecan is different from that of cell surface syndecan. 
Since perlecan upregulation may be part of the thickening of BM in the 
vasculature which contributes to endothelial dysfunction, insulin or heparin 
may have the ability to protect endothelium. Interestingly, we found the 
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combination of heparin and insulin not only increased mRNA of syndecan, 
but also heparanase in the presence of high glucose. It is understandable 
that heparin and insulin may synergistically increase syndecan production to 
protect ECs, since heparin and insulin in combination protected cells from 
high glucose and heparinase injury (Han et al., 2005). However, the 
mechanism of heparin and insulin increased heparanase mRNA can not be 
elucidated in the present study. It is possible that high glucose, insulin or 
heparin regulate heparanase gene expression through synergistically 
activating different transcriptional factors on the heparanase promoter region. 
In addition, the protective effect of heparin and/or insulin on ECs injured by 
high glucose is shown by reduced EC intercellular gaps and inhibition of 
heparanase upregulation (Mandal et al., 2000; Han et al., 2007). As 
mentioned above, heparin and insulin interact with and function by different 
mechanisms on HSPGs, and may collectively and synergistically activate or 
inactivate gene expression of syndecan, perlecan and heparanase under 
hyperglycaemic conditions. Increased mRNA levels may not reflect increased 
active protein in these experiments, or increases may occur that are 
insufficient to affect proteoglycan synthesis. This is an area that requires 
further experimentation through investigation of gene regulation at the 
transcriptional level.  
            In summary, the investigation of gene expression of heparanase, 
syndecan and perlecan in ECs under hyperglycemic condition in the present 
study revealed high glucose induced heparanase, decreased syndecan and 
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had no effect on perlecan gene expression. The effect of insulin and heparin 
alone or in combination on gene expression varied depending on the 
presence or absence of high glucose, indicating that the regulatory 
complexity of these genes by high glucose and/or insulin and/or heparin. 
Further studies in transcriptional factors involved in the mechanism of gene 
regulation will lay the foundation for understanding genetic alteration in 
diabetic vascular complications and the therapeutic functions of insulin and 
heparin at the level of gene regulation. 
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6. Prediction of Promoter Regions and Possible                                                                                                                                     
Transcription Factors on the Genes of Heparanase,  
Perlecan and Syndecan  
            To better understand the mechanisms of gene expression of 
heparanase, perlecan and syndecan, the promoter regions and possible 
transcription factor binding sites for these three genes were analyzed by 
Proscan from BIMAS (BioInformatics and Molecular Analysis Section) 
            Heparanase: The promoter region was found on the forward strand 
up to 3000 bp before the gene transcriptional region. Possible transcriptional 
factor binding sites found at this region are JCV_repeated_sequence, two 
Sp1 and EARLY-SEQ1. It has been shown that the heparanase promoter 
does not contain TATA or CAAT box but contains a GC-rich sequence in the 
proximal promoter region. The basal promoter activity of the heparanase 
gene is largely located in a 0.3-kb region upstream of the translation start site 
(Maxhimer et al., 2005). Three Sp1 sites and four ETS (transcription factor 
family) relevant elements were identified in this region (Jiang et al., 2002). 
The ability of glucose to transcriptionally activate heparanase promoter rests 
largely within the 0.3-kb region upstream of the translational start site (Jiang 
et al., 2002). Previous studies have demonstrated that high glucose is able to 
activate several transcription factors that are involved in regulation of the 
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heparanase promoter, including Sp1, Egr-1 (Early growth response factor 1) 
and the ETS family transcription factors (Jiang et al., 2002). A study of 
induction of heparanase expression in renal epithelial cells by high glucose 
showed that concerted activation of these transcription factors by high 
glucose leads to the activation of heparanase promoter and induction of 
heparanase gene expression  (Maxhimer et al., 2005). 
            Perlecan: Promoter region was predicted on the perlecan forward 
strand up to 2000 bp before the gene transcriptional region. The possible 
transcriptional factors that bind to this region are Sp1, 
JCV_repeated_sequence, GCF, AP-2, EARLY-SEQ1 and NGFI-C. A study 
on perlecan promoter by Cohen et al showed that a characteristic of the 
human perlecan promoter is the presence of potential sites for binding of 
several transcription factors, including Sp1, Ap-2 and ETF. The promoter is 
highly enriched in GC content, contains four GC boxes and three GGGCGG 
hexanucleotide sequences, which are known to bind the transcription factor 
Sp1 (Cohen et al., 1993). However, direct examination of regulation of the 
perlecan gene by these transcriptional factors remains to be performed.  
            Syndecan: The prediction of the human syndecan promoter region 
by Proscan from BIMAS resulted in no promoter regions on the syndecan 
forward strand up to 2000-4000 bp before the gene transcriptional region. 
This result indicates that the studies on promoter regions of human 
syndecans are limited. Studies on mouse cell surface HSPG genes have 
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shown that potential binding sites for several transcription factors have been 
identified in the upstream sequence of these genes including NF-kB, Myo-D, 
Antennapedia-binding site and multiple proximal Sp-1 binding sites on 
syndecan-1. Sp1-like transcription factors have an essential role in the 
regulation of the transcriptional activity of the syndecan-1 gene (Hinkes et al., 
1993; Larrain et al., 1997; Tsuzuki et al., 1997; Vihinen et al., 1996). The 
expression of syndecan-1 during myoblast terminal differentiation was down-
regulated due to the variations in Sp1 activity (Vihinen et al., 1996). Similarly, 
the expression of perlecan during myogenesis is also down-regulated 
(Larrain et al., 1997). The promoter region of perlecan resembles that of 
mouse syndecan-1, suggesting that similar regulatory mechanisms are 
involved in the regulation of these two macromolecules (Cohen et al., 1993; 
Vihinen et al., 1996). 
            The prediction and studies of promoter and transcription factors for 
genes of heparanase, perlecan and syndecan imply that the transcription 
factor Sp1 is a common factor for the regulation of the three genes. Sp1 is a 
human transcription factor involved in gene expression in the early 
development of an organism. The protein is 785 amino acids long, with a 
molecular weight of 81 KDa. It contains a zinc finger protein motif, by which it 
binds directly to DNA and enhances gene transcription. Its zinc finger binds 
the consensus sequence 5’-(G/T)GGGCGG(G/A)(C/T)-3’(GC box element). 
Sp1 has been shown to be involved in regulation of heparanase promoter by 
high glucose activation. Sp1 may play a role in regulation of promoters of 
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perlecan and syndecan by high glucose activation. Elucidation of 
transcriptional functions of Sp1 on the promoters of heparanase, perlecan 
and syndecan may provide the fundamental mechanisms of alterations of 
HSPG in hyperglycemia providing further understanding of diabetic vascular 
complications due to endothelial injury. 
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7. GENERAL DISCUSSION 
            HSPGs are macromolecules containing a core protein with GAG 
chains attached that are mostly HS. ECs synthesize two main types of HSPG 
in the vasculature, syndecans on the cell surface and perlecan in ECM. 
HSPG metabolism and degradation can be pathophysiologically affected at 
different levels including synthesis of core protein and GAG chains (Esko and 
Lindahl, 2001). Core protein synthesis is controlled by transcription of DNA to 
mRNA and translation of mRNA to protein. GAG chain synthesis is directed 
by chain addition, elongation, sulfation and degradation. Changes in HSPG 
synthesis and turnover will affect the endothelium to a large extent. HSPGs 
are believed to be the endogenous receptors for circulating growth factors 
and chemokines that regulate cell proliferation, differentiation and migration 
and possesses functions of membrane filtering and cell signaling. Therefore, 
degradation of HSPG may cause increased vascular permeability and 
damage to the vascular wall. One of the pathological mechanisms of diabetic 
cardiovascular complications is endothelial dysfunction or injury, caused by 
HSPG degradation induced by hyperglycemia.  
            In the present study, our results show for the first time in ECs, that 
high glucose decreased GAG content in PAECs and decreased syndecan 
gene and increased heparanase gene expression in PAECs and that insulin 
decreased GAGs in PAECs and medium suggesting insulin may inhibit GAG 
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synthesis and play a role in GAG degradation. As well our results showed 
that insulin or heparin protected GAGs from high glucose degradation in 
PAECs; and insulin and/or heparin upregulated syndecan and heparanase, 
and downregulated perlecan gene expression in the presence of high 
glucose in HAECs. In addition, HPLC analysis of HS disaccharides in PAECs 
showed different missing disaccharides in cells versus medium and control 
medium versus glucose treated medium.   
            Decreased total GAGs in high glucose-treated ECs is consistent with 
previous studies that the content of HS and HSPG was reduced in glomerular 
and skin BM and in the aortic intima of diabetic patients. It is possible that 
reduction of total GAGs by high glucose was partly caused by decreased 
syndecan mRNA and increased heparanase mRNA shown in this study 
(Figure 5.1 and 5.2), since heparanase degrades HS chains on syndecans 
or perlecan (Reiland et al., 2004). Heparanase protein had been localized in 
both glomeruli capillaries and tubular epithelium and heparanase activity was 
detected in the urine of diabetic patients and high glucose-treated PAECs 
(Han et al., 2007; Katz et al., 2002; Shafat et al., 2006). Since heparanase 
does not change syndecan core protein (Reiland et al., 2004), HS reduction 
due to decreased syndecan mRNA by high glucose may not correlate with 
heparanase induction. In addition, the degradation of cell surface HSPG was 
reversed by heparanase inhibitors, PI-88 and heparin, in epithelial cells 
under hyperglycaemic conditions (Maxhimer et al., 2005) further confirming 
that heparanase induction is the cause of HS chain degradation. However, 
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an increase in serum syndecan was shown in early nephropathy of diabetic 
patients (Svennevig et al., 2006) and heparanase was responsible for 
syndecan shedding in myeloma and breast cancer cells (Yang et al., 2007). 
These observations suggest that increased serum syndecan in the diabetic 
patient may be due to heparanase induction which may play a role in 
decreased syndecan core protein and HS, but not expression of syndecan 
mRNA in ECs. 
            Vascular endothelium is a physiological target of insulin and a 
potential link between insulin resistance and atherosclerosis (Hsueh and 
Law, 1999; Mather et al., 2001a). Insulin acts on vascular cells by modulating 
transcription, altering cell content of numerous mRNAs and stimulating cell 
growth, DNA synthesis and replication (Bornfeldt et al., 1992; Sowers, 1997). 
Our studies demonstrated that insulin also plays a role in GAG synthesis or 
degradation.  There was a trend that insulin alone increased GAGs in culture 
medium as culturing time increased (Figure 3.4.B) which may indicate 
HSPG degradation, turnover or shedding of HS or syndecan into medium. 
GAGs were significantly reduced in 72 hour insulin alone treated cultures 
compared to control, suggesting that GAG synthesis may also be inhibited 
(Figure 3.4.C). Insulin alone decreased heparanase and perlecan mRNA in 
the presence and absence of high glucose and syndecan in the presence of 
high glucose, suggesting that insulin may protect cells by inhibiting 
heparanase mRNA and may be harmful to cells by decreasing perlecan and 
syndecan mRNA. These data suggest the dual actions of insulin on ECs. On 
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the one hand, insulin inhibited heparanase mRNA expression in high 
glucose-treated cells and protected cell injury by HS degradation caused by 
heparanase upregulation. As well, insulin alone inhibited perlecan and 
syndecan mRNA expression and may shed syndecan ectodomains from the 
cell surface which are harmful to ECs, since insulin promoted shedding of 
syndecan ectodomains from 3T3-L1 adipocytes (Reizes et al., 2006). In a 
study of regulation of HSPG metabolism and hepatocyte growth by insulin, 
insulin markedly stimulated the rate of internalization of matrix HSPG and 
phospholipase C and therefore may control cell surface or matrix HSPG 
turnover (Ishihara et al., 1987). 
            Previous studies have shown that heparin increased HS synthesis, 
prevented heparanase upregulation in ECs and HSPG degradation from 
heparanase induction (Bar-Ner et al., 1987; Han et al., 2007; Nader et al., 
1991). In the present study, heparin increased GAGs in high glucose-treated 
cultures (Figure 3.6) and protected syndecan mRNA from high glucose 
degradation which are consistent with the previous observations. Heparin 
alone or in the presence of high glucose decreased heparanase and 
perlecan, increased syndecan mRNA expression and further confirmed that 
heparin is capable of inhibiting heparanase expression under high glucose 
conditions and enhancing the synthetic formation of syndecan, but not 
perlecan. These results suggest that heparin plays a role in the protection of 
endothelium and vasculature by increasing syndecan synthesis and 
preventing of heparanase induction.  
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            Addition of actinomycin D inhibited both β-actin and heparanase 
mRNA expression under high glucose conditions (Figure 5.4), suggesting 
transcriptional regulation of high glucose on heparanase gene expression 
occurs in ECs. Previous studies have demonstrated that high glucose is able 
to activate several transcriptional factors that are involved in regulation of the  
heparanase promoter, including Sp1, Egr-1 and the ETS family transcription 
factors (Jiang et al., 2002). These transcription factors play a role in 
controlling the basal activity of human heparanase gene expression (Jiang et 
al., 2002; Lu et al., 2003). Increased mRNAs of syndecan and heparanase 
and decreased perlecan mRNA in high glucose plus insulin plus heparin 
treated cultures indicated that the influence of heparin and insulin on 
expression of these three genes was complicated in the presence of high 
glucose. Addition of actinomycin D in high glucose plus insulin plus heparin 
treated cultures inhibited genes of heparanase and syndecan as well as β-
actin (Figure 5.5 and 5.6), suggesting transcriptional regulation of these two 
genes by a combination of insulin and heparin under hyperglycemic 
conditions. The syndecan gene is regulated by Sp1-like transcription factors 
(Vihinen et al., 1996). Phosphorylation of Sp1 by the PKC family may change 
its abundance or transactivation activity (Black et al., 2001). Phosphorylation 
of Sp1 by PKC decreased its activity (Leggett et al., 1995). A decrease in 
Sp1 activity may cause down-regulation of syndecan gene expression in ECs 
under hyperglycaemic conditions, since glucose can activate and upregulate 
PKC (Scivittaro et al., 2000). Although perlecan mRNA was not changed by 
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high glucose in the present study, expression may be posttranscriptionally 
regulated, since perlecan expression was down-regulated by cAMP alone in 
glomerular epithelial cells through posttranscriptional events (Ko et al., 1996).  
Heparin prevented binding of AP-1, but not Sp1 to their binding site on TGF-
β and circumvented the prosclerotic pathogenesis in diabetic nephropathy 
(Weigert et al., 2001). Insulin upregulated PAI-1 by activating Sp1 
transcription factor (Banfi et al., 2001).  In contrast, over-expression of Sp1 in 
rat hepatocytes leads to a decrease in FAS promoter activity (Fukada et al., 
1997). Heparin or insulin may regulate gene expression by interacting with 
different transcriptional factors or acting differently on common transcriptional 
binding sites such as Sp1 through diverse pathways with positive or negative 
regulations. It is possible that there are alternative sites regulated by heparin, 
insulin or glucose on the promoters of heparanase, syndecan, and perlecan 
genes. The decreased mRNA expression of heparanase and perlecan by 
insulin alone may be due to Sp1 activated by insulin, which may play a 
negative transcriptional role at promoter regions of heparanase and perlecan. 
Syndecan mRNA expression decreased by high glucose and not changed by 
insulin in this study may suggest opposite actions of glucose and insulin on 
Sp1 regulation. However, insulin promoted shedding of syndecan, and the 
similar sequences between the human insulin receptor and mouse syndecan 
(Ebina et al., 1985) may mean that insulin affects the pathways involved in 
syndecan biosynthesis or turnover.  Therefore, insulin may play a role in 
posttranscriptional regulation of syndecan expression and reduce syndecan 
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on cell surface although syndecan mRNA wasn’t effected by insulin in the 
present study.         
            In conclusion, alteration of HSPGs, either the core protein or GAG 
chains by high glucose, influences EC functions and activities. Decreased 
total GAG content and syndecan mRNA, and increased heparanase mRNA 
by high glucose suggests that high glucose is detrimental to ECs. 
Dysfunction or injury of ECs induced by HSPG degradation is responsible for 
diabetic vascular complications. Interestingly, we also found that insulin, an 
effective glucose lowering therapy, also reduced total GAGs in cells and 
medium suggesting a potential mechanism of insulin resistance or 
hyperinsulinemia.  Heparin showed a protective effect on ECs by increasing 
GAG content and syndecan mRNA as well as decreasing heparanase 
mRNA. Combination of insulin and heparin synergistically enhanced 
syndecan and heparanase mRNA expression, suggesting complex the gene 
regulation mechanisms by several transcriptional factors are involved in the 
regulation of these genes. Furthermore, enhanced heparanase mRNA 
expression by high glucose plus insulin plus heparin may raise precautions 
when using insulin and heparin for therapeutic purposes in diabetic 
treatment. 
            The present study has several limitations. The size of cell culture 
dishes is important for extracting enough GAGs from cells for analysis. 
Enough GAGs could not be obtained from a single 60 mm dish, but three 60 
mm dishes combined provide enough GAGs for HPLC analysis of HS 
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disaccharides. More primary PAECs were needed for passing cells to bigger 
(100 mm) dishes. When using these large dishes, it takes a longer time for 
cells to grow to confluence and become evenly distributed which may affect 
cell health and viability as well as GAG synthesis. It is even harder to grow 
ample uniform human ECs for GAG studies due to the unstable quality or 
diverse sources of commercially available cultured HAECs.  
            Heparin interferes with the GAG content in ECs. The carbazole assay 
determines all GAGs including heparin and can not be performed in heparin  
treated cells, therefore the effect of heparin and/or insulin addition on total 
GAG content could not be measured and evaluated by the carbazole assay 
in this study. HAECs but not PAECs were used to determine gene 
expression in this study due to gene sequences for heparanase, syndecan 
and perlecan being available for human but not porcine species. There is a 
limitation to cooperatively integrate and interpret the two studies mentioned 
above because we used cells from two different species. These are in vitro 
studies where results cannot be completely applied to elucidate the in vivo 
situation, since ECs in the vasculature reside in enviroments different from 
culture medium.  Further investigations in in vivo studies will provide more 
accurate consequences of GAG changes and gene expression in 
pathological mechanisms of hyperglycemia and the therapeutic outcome of 
heparin and/or insulin on diabetes. 
            Future studies:  A dose response determination for heparin and 
insulin needs to be performed in order to select the right dose for obvious 
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effects of these two compounds on GAG changes and gene expression. 
Analysis of enzymes involved in HS synthesis such as 3OSTs, NDSTs, and 
6OSTs in high glucose-treated ECs will provide information on the 
fundamental mechanisms of HSPG degadation under hyperglycemic 
conditions. Determining changes in different HS disaccharides by HPLC in 
high glucose-treated ECs will confirm the enzyme analysis. Elucidation of 
transcriptional factors on the promoters of heparanase, perlecan and 
syndecan, especially some common expressed factors such as Sp1 and the 
effect of insulin and heparin will help to further understand gene regulatory 
mechanisms of HSPG core proteins in hyperglycemia as well as the 
therapeutic funtions of insulin and heparin in diabetes. 
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